Introduction {#s1}
============

Hypothalamic arcuate nucleus kisspeptin (Kiss1^ARH^) neurons and anteroventral periventricular and periventricular nucleus Kiss1 (Kiss1^AVPV/PeN^) neurons are regulated in a species-, sex, and gonadal steroid-specific manner ([@bib23]; [@bib38]; [@bib63]; [@bib74] [@bib73]). Kiss1^AVPV/PeN^ neurons are essential for positive feedback by estradiol on gonadotropin-releasing hormone (GnRH) neuronal activity and the luteinizing hormone (LH) surge in rodents ([@bib12]). 17β-estradiol (E2) increases *Kiss1* mRNA expression in these rostral Kiss1 neurons ([@bib72]), and their excitability is increased by the E2-driven upregulation of T-type calcium, hyperpolarization-activated, cyclic-nucleotide gated (h)- and persistent sodium (I~NaP~) currents ([@bib55]; [@bib81]; [@bib84],[@bib85]). In addition, glutamate induces burst firing and pacemaking activity in Kiss1^AVPV/PeN^ neurons ([@bib80]; [@bib85]).

In contrast to the Kiss1^AVPV/PeN^ neurons, E2 significantly inhibits *Kiss1* mRNA expression in ARH neurons ([@bib37]; [@bib45]; [@bib72]). However, the effect of E2 on ion channel expression and excitability is less clear in Kiss1^ARH^ neurons, and we do not fully understand the mechanism(s) by which E2 affects the excitability of the Kiss1^ARH^ neuronal population ([@bib84]). Kiss1^ARH^ neurons co-express the peptide neurotransmitters kisspeptin (Kiss1), tachykinin 2 (Tac2; *a.k.a*. neurokinin B; NKB) and dynorphin ([@bib38]), which have been proposed to be responsible for pulsatile release of GnRH and LH ([@bib13]; [@bib39]; [@bib45]). Indeed, the cellular mechanisms by which Kiss1^ARH^ neurons synchronize to drive GnRH pulses was recently elucidated and involves a combination of co-released Tac2 excitation via Tac3 receptors and dynorphin presynaptic inhibition via κ-opioid receptors ([@bib61]). Kiss1^ARH^ neurons also express the vesicular glutamate transporter 2 (vGluT2) ([@bib16]; [@bib46]), an indication that they have the potential to package and release the neurotransmitter glutamate ([@bib34]). Optogenetic activation of Kiss1^ARH^ neurons evokes glutamatergic EPSCs not only in Kiss1^AVPV/PeN^ neurons ([@bib61]) but also in proopiomelanocortin (POMC) and neuropeptide Y/agouti-related peptide (NPY/AgRP) neurons ([@bib46]), which further establishes direct functional connections between Kiss1^ARH^ neurons and hypothalamic neurons important for the control of reproduction and energy homeostasis. In males, *Slc17a6* (encodes vGluT2) mRNA and glutamate release are increased in gonadectomized as compared to intact animals, an indication of inhibitory effects of gonadal steroids on glutamate neurotransmission in these neurons ([@bib46]). Based on pronounced male/female differences in feeding behavior and the excitatory glutamatergic input from Kiss1^ARH^ neurons to Kiss1^AVPV/PeN^ neurons in females ([@bib2]; [@bib61]), we hypothesized that the mRNA expression of *Slc17a6* and glutamate release in females in contrast to males, would be amplified by E2 in Kiss1^ARH^ neurons in order to help maintain reproduction during different energy states. Therefore, we investigated the effects of ovariectomy (OVX) and E2-replacement on neuronal excitability as well as the effect of E2 on mRNA expression of *Slc17a6* in Kiss1^ARH^ neurons and the release of glutamate from these neurons onto Kiss1^AVPV/PeN^, POMC and NPY/AgRP neurons. Also, to evaluate the main functional role of glutamate release from Kiss1^ARH^ neurons in females, we deleted the expression of *Slc17a6* in Kiss1 neurons and measured electrophysiological changes in Kiss1^ARH^ neuronal transmission as well as behavioral changes in vivo.

Results {#s2}
=======

Estradiol treatment reduces the mRNA expression of neuropeptides while increasing the expression of the T-type calcium channels, HCN channels, and the excitability of Kiss1^ARH^ neurons {#s2-1}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

It has been shown repeatedly in a number of species, that the mRNA expression of the peptide neurotransmitters kisspeptin, Tac2 and dynorphin, which are co-expressed in Kiss1^ARH^ neurons, is increased in OVX animals and reduced in E2-treated animals ([@bib38]). However, vGluT2 is also expressed in Kiss1^ARH^ neurons ([@bib16]; [@bib46]), and *Slc17a6* mRNA levels are reduced in intact as compared to castrated males, an indication of sex-steroid regulation ([@bib46]). Currently, we used a sensitive real-time qPCR assay to measure relative quantitative differences of *Kiss1, Tac2, Pdyn, Tacr3*, *Slc17a6* and ion channels in manually-harvested Kiss1^ARH^ neurons in OVX as compared to E2-treated females ([Figures 1](#fig1){ref-type="fig"}--[3](#fig3){ref-type="fig"}). Based on the CT values ([Figure 1](#fig1){ref-type="fig"}) and quantitative analysis with *Tacr3* as calibrator (see Materials and Methods), *Tac2* mRNA was the most highly expressed in Kiss1^ARH^ neurons from OVX females, such that *Tac2 \>\>\>* (50-fold) *Pdyn ≥Kiss1 \>\>* (6-fold) *Slc17a6*, and with E2 treatment, *Tac2 \>\>* (18-fold) *Pdyn \>\>* (2-fold) *Slc17a6 \>* (2-fold) *Kiss1* (one-way ANOVA). These results suggested that there could be a dramatic change in the Kiss1^ARH^ neuronal synaptic transmission to various target neurons (see below for further quantitative and functional analyses).

![qPCR amplification assay illustrating the cycle threshold (CT) for the different neuropeptides and vGluT2 in Kiss1^ARH^ neurons.\
Cycle number is plotted against the normalized fluorescence intensity (∆RN) to visualize the PCR amplification of *Tac2*, *Pdyn*, *Kiss1*, *Tacr3*, *Slc17a6* and the reference gene *Gapdh* in 5 cell Kiss1^ARH^ pools obtained from oil- and E2-treated, OVX animals. The amplification efficiency for each primer pair is listed in [Table 1](#table1){ref-type="table"}. These efficiencies allowed us to use the comparative ∆∆CT methods for quantification. The cycle threshold (CT; horizontal dashed line) is the point in the amplification from which sample values were calculated using the 2^-∆∆CT^ equation as described in the Methods.\
10.7554/eLife.35656.003Figure 1---source data 1.OVX + Oil Gene comparisons (fold change generated using OVX + Oil Tacr3 as calibrator) and OVX + E2 Gene comparisons.](elife-35656-fig1){#fig1}

![Estradiol regulation of ion channel mRNA expression and excitability of Kiss1^ARH^ Neurons.\
(**A**) Quantitative real-time PCR measurements of *Cacna1g* (*Cav3.1), HCN1, HCN2, Kiss1* and *Pdyn* mRNAs in Kiss1^ARH^ neuronal pools (3 pools of 5 cells each per animal) from OVX oil- and E2-treated mice (n = 5--6 animals per group). Note that E2 increased the mRNA expression of *Cacna1g, Hcn1, Hcn2,* but as expected decreased the mRNA expression of *Kiss1* and *Pdyn* in the same Kiss1 neuronal pools (for, *Cacna1g*, Unpaired t-test t~(10)~ = 6.037, p\<0.001; *Hcn1*, Unpaired t-test, t~(8)~ = 10.13, p\<0.0001; *Hcn2*, Unpaired t-test, t~(8)~ = 3.420, p\<0.01; *Kiss1*, Unpaired t-test, t~(8)~ = 6.348, p\<0.001; *Pdyn*, Unpaired t-test, t~(8)~ = 6.118, p\<0.001). (**B**) T-type calcium current and h-current density (pA/pF) in Kiss1^ARH^ neurons from OVX oil- and E2-treated mice (for T-current, t~(19)~ = 6.956, p\<0.0001; for h-current, t~(19)~ = 6.964, p\<0.0001; n = 9--12 neurons from 8 animals). Current densities were measured as previously described ([@bib85]). (**C**) Example of rebound burst firing in Kiss1^ARH^ neurons (left), which increased fast Na^+^ spiking with E2, and summary data (right) from oil- versus E2-treated females (n = 10 and 25 neurons, respectively). Rebound firing was measured as previously described ([@bib85]). Bar graphs represent the mean ±SEM, (Unpaired t-test, t~(33)~ = 4.455, p\<0.0001). \*\*p\<0.01, \*\*\*p\<0.001.\
10.7554/eLife.35656.005Figure 2---source data 1.*Cacna1g, Hcn1, Hcn2, Kiss1* and *Pdyn* expression in Kiss1-ARH neurons ([Figure 2A](#fig2){ref-type="fig"}).T-type calcium current and h-current density (pA/pF) in Kiss1^ARH^ neurons from OVX oil- and E2-treated mice ([Figure 2B](#fig2){ref-type="fig"}). Summary data of rebound burst firing in Kiss1^ARH^ neurons from oil- versus E2-treated females ([Figure 2C](#fig2){ref-type="fig"}).](elife-35656-fig2){#fig2}

![Estradiol regulation of *Slc17a6* mRNA expression in Kiss1^ARH^ neurons.\
Quantitative real-time PCR measurements of *Slc17a6*, *Tac2* and *Tacr3* mRNAs in Kiss1^ARH^ neuronal pools (3--6 pools of 5 cells each per animal) from OVX oil- and E2-treated mice (n = 4--7 animals per group). Note that E2 increased the mRNA expression of *Slc17a6,* but as expected decreased the mRNA expression of *Tac2* and *Tacr3* in the same Kiss1 neuronal pools. Bar graphs represent the mean ±SEM (for *Slc17a6*, Unpaired t-test, t~(8)~ = 4.522, p\<0.001; *Tac2*, Unpaired t-test, t~(8)~ = 6.350, p\<0.001; *Tacr3*, Unpaired t-test, t~(6)~ = 7.161, p\<0.001). \*\*\*p\<0.001.\
10.7554/eLife.35656.007Figure 3---source data 1.*Slc17a6, Tac2, Tacr3* expression in Kiss1-ARH neurons.](elife-35656-fig3){#fig3}

Previously, we found that an E2-treatment that induces an LH surge in OVX females increases mRNA expression and/or function of a number of ion channels important for neuronal excitability, including T-type calcium channel subunit Ca~V~3.1, sodium channel subunits N~aV~ 1.1α and N~aV~ β2 and the corresponding currents I~T~, I~NaP~ and I~h~ in Kiss1^AVPV/PeN^ neurons ([@bib84], [@bib85]). Since the channels that underlie the pacemaking activity of Kiss1^AVPV/PeN^ neurons (N~aV~ 1.1α, N~aV~ β2 mRNA and I~NaP~) were not altered by E2-treatment in Kiss1^ARH^ neurons ([@bib84]), we hypothesized that E2 similarly would not alter *Cacna1g* mRNA (encoding Cav3.1), *Hcn* mRNA expression or the associated T-type calcium- and h- currents, respectively, in Kiss1^ARH^ neurons. Surprisingly, we found that the mRNA expression of *Cacna1g* and *Hcn1* and *Hcn2* were significantly increased in Kiss1^ARH^ neurons from E2-treated females as compared to oil-treated, OVX females ([Figure 2A](#fig2){ref-type="fig"}). For comparison we also measured *Kiss1* and *Pdyn* mRNAs in the same neuronal pools, and as predicted, *Kiss1* and *Pdyn* mRNA levels were significantly reduced by E2 ([Figure 2A](#fig2){ref-type="fig"}). In addition, both T- and h-currents ([Figure 2B](#fig2){ref-type="fig"}) as well as neuronal excitability (measured as rebound excitation; [Figure 2C](#fig2){ref-type="fig"}) were increased in Kiss1^ARH^ neurons with E2-treatment as compared to oil-treatment. Therefore, although E2-treatment downregulates neuropeptide expression in Kiss1^ARH^ neurons, it significantly increases the intrinsic conductances and hence the excitability of these vital neurons.

The mRNA for vGluT2 is up-regulated by E2-treatment in Kiss1^ARH^ neurons {#s2-2}
-------------------------------------------------------------------------

Having found previously that Kiss1^ARH^ neurons express *Slc17a6* (encodes vGluT2) and release glutamate onto POA neurons and ARH POMC and NPY/AgRP neurons ([@bib46]; [@bib61]), we hypothesized that E2 would increase glutamatergic input to Kiss1^AVPV/PeN^ neurons to positively influence fertility and glutamatergic input onto NPY and POMC neurons to affect feeding behavior in females. Therefore, we performed quantitative analysis of *Slc17a6*, and *Slc32a1* (encodes vGAT) in oil- and E2-treated, OVX females to explore potential E2 regulation. The qPCR analysis revealed that Kiss1^ARH^ neurons (5 cells/pool; 3--6 pools/animal) in E2-treated, OVX female mice expressed approximately 2-fold higher levels of *Slc17a6* mRNA than oil-treated, OVX mice ([Figure 3](#fig3){ref-type="fig"}), while the level of *Slc32a1* mRNA was undetectable in Kiss1^ARH^ neurons from both groups of female mice (data not shown). For comparison we also measured *Tac2* and *Tacr3* mRNAs in the same Kiss1^ARH^ neuronal pools, and as expected, the mRNA expression of these transcripts were both significantly reduced in E2-treated females ([Figure 3](#fig3){ref-type="fig"}). Therefore, the E2-induced increased *Slc17a6* mRNA expression in Kiss1^ARH^ neurons is an indication that the amino acid neurotransmitter glutamate is regulated differently by E2 than the neuropeptides in females.

Glutamate, not GABA, is released from Kiss1^ARH^ neurons {#s2-3}
--------------------------------------------------------

Using whole-cell, voltage-clamp recordings in slices from OVX female mice, we initially examined evoked (photostimulated) PSCs in ARH NPY/AgRP neurons from *Kiss1^Cre:GFP^::Npy^GFP^* mice or in POMC neurons from *Kiss1^Cre:GFP^::Pomc^EGFP^* mice that had received a bilateral injection of AAV1-ChR2-mCherry (or ChR2-YFP) into the ARH ([Figure 4A,B](#fig4){ref-type="fig"}). Subsequently, we performed blind whole-cell patch recordings from POMC and NPY/AgRP neurons in *Kiss1^Cre:GFP^* mice that had received a bilateral injection of AAV1-ChR2-mCherry (or ChR2-YFP) into the ARH. For the latter group we could segregate the medially located, higher input resistance (1.6 ± 0.2 GΩ), lower capacitance (\~18.4 ± 1.0 pF) NPY/AgRP neurons from the more laterally located, lower input resistance (\~1.2 ± 0.2 GΩ), higher capacitance (\~24.4 ± 1.3 pF) POMC neurons ([@bib59]; [@bib70]). In total, seventy-seven cells showed an inward current following photostimulation with a mean amplitude of 29.8 ± 3.4 pA, a mean latency to peak of 4.0 ± 0.1 ms, and an average decay time constant of 5.5 ± 0.6 ms. This light-induced response was blocked with the AMPA- and NMDA-receptor blockers, CNQX and AP5, respectively ([Figure 4C](#fig4){ref-type="fig"}). Therefore, glutamate, and not GABA, is the primary amino acid neurotransmitter released from Kiss1^ARH^ neurons in females. Moreover, although TTX (1 μM) abrogated the photostimulated post-synaptic inward current, we could rescue the light-induced response with the addition of the potassium channel blocker 4-AP (100 μM to the bath) in both POMC (n = 3) and NPY/AgRP (n = 2) neurons ([Figure 4D,E](#fig4){ref-type="fig"}), which is biophysical evidence for direct synaptic signaling from Kiss1^ARH^ neurons to POMC and NPY/AgRP neurons ([@bib14]; [@bib53]). Following recording, the cytoplasm of numerous responsive cells was collected and analyzed for mRNA transcripts (*Pomc*, *Npy*, and *Kiss1*) using scRT-PCR to confirm our targeting strategy described above ([Figure 4D,E](#fig4){ref-type="fig"}, Insets). Based on this analysis, there was no difference in the amplitude of the evoked fast PSCs between POMC and NPY neurons (*post-hoc* identified) (25.8 ± 4.8 pA, n = 36 POMC neurons versus 33.3 ± 4.9 pA, n = 41 NPY/AgRP neurons). Therefore, it appears that when Kiss1^ARH^ neurons in the female are firing at low frequencies there is equivalent fast (ionotropic) glutamatergic input to both POMC and NPY/AgRP neurons in the female, similar to what we found in males ([@bib46]).

![Optogenetic activation of Kiss1-ARH neurons directly excites POMC and NPY/AgRP neurons via glutamate release.\
(**A**) AAV1-DIO-ChR2:mCherry was bilaterally injected into ARH of Kiss1^Cre^: : *Npy*^GFP^ mice or Kiss1^Cre^: : Pomc^EGFP^ (not shown). (**B**), schematic of experimental design; whole-cell, voltage-clamp (V~hold~ = −60 mV) recordings were made in POMC^EGFP^ or NPY^GFP^ neurons and a single pulse (intensity, 660 μW; 10 ms duration) of blue light (470 nm) was delivered to the ARH. (**C**), a fast inward current was recorded in both POMC and NPY neurons (yellow trace is average) that was antagonized by CNQX (10 µM) and AP5 (50 µM) (red trace). (**D,E**), the optogenetic (glutamate) response (green trace) was abrogated in the presence of TTX (1 µM, black trace) but rescued with the addition of the K^+^ channel blocker 4-AP (100 µM, magenta trace) in both POMC (**D**) and NPY (**E**) neurons, n = 3 and 2, respectively. Insets show the scRT-PCR *post hoc* identification of representative recorded *Pomc* and *Npy* neurons. RC, recorded cell; +, positive control (with reverse transcriptase); -, negative control (without reverse transcriptase); MM, molecular marker.](elife-35656-fig4){#fig4}

Steroid-dependent glutamate release from Kiss1^ARH^ neurons {#s2-4}
-----------------------------------------------------------

E2-treatment of OVX females increased the mRNA expression of *Slc17a6* in Kiss1^ARH^ neurons, and synaptic glutamate release is tightly coupled to vGluT2 expression ([@bib34]). Therefore, we explored the differences in evoked glutamate release from Kiss1^ARH^ neurons using a paired-pulse-ratio paradigm (PPR: ratio of the amplitude of the second pulse over the amplitude of the first pulse) ([@bib86]) in control (oil) and E2-treated OVX *Kiss1^Cre:GFP^*, *Kiss1^Cre:GFP^::Npy^GFP^* and *Kiss1^Cre:GFP^::Pomc^EGFP^* female mice that received a bilateral injection of AAV1-DIO-ChR2:mCherry (or AAV1-DIO-ChR2:YFP) into the ARH. Using a photostimulation PPR protocol of two 5 ms LED stimulations separated by 50 ms ([Figure 5A,B](#fig5){ref-type="fig"}), we found that POMC and NPY/AgRP neurons in E2-treated, OVX female mice had a significantly lower PPR compared to oil-treated, OVX females in both POMC neurons ([Figure 5C,D](#fig5){ref-type="fig"}) and in NPY/AgRP neurons ([Figure 5E,F](#fig5){ref-type="fig"}). These results indicate that there is a greater probability of glutamate release with the first stimulus in E2-treated, OVX animals ([Figure 5B](#fig5){ref-type="fig"}), which is consistent with higher mRNA expression of *Slc17a6* in Kiss1^ARH^ neurons following E2-treatment. Collectively, these data indicate that there is a striking male/female difference concerning the effects of sex steroids (testosterone versus estradiol) on *Slc17a6* mRNA expression and glutamate release in Kiss1^ARH^ neurons ([@bib46]).

![E2-treatment increases glutamate release from Kiss1^ARH^ neurons onto POMC and NPY neurons.\
(**A**) schematic of photostimulation of cells/terminals of Kiss1^ARH^ neurons and recording from POMC or NPY/AgRP neurons. (**B**), illustration of a paired-pulse regime (two blue light pulses of 5 ms duration separated by 50 ms); fast glutamatergic inward currents (P1 and P2) were recorded to measure the probability of neurotransmitter release in postsynaptic neurons. (**C**), AAV1-DIO-ChR2:mCherry was bilaterally injected into ARH of Kiss1^Cre^::*Npy*^GFP^ mice or Kiss1^Cre^::Pomc^EGFP^ mice. Using a paired-pulse regime, fast glutamatergic inward currents were recorded in POMC^EGFP^ neurons (V~hold~ = −60 mV) from both oil-treated, OVX (upper trace, black) and E2-treated, OVX (lower trace, red) females. The averaged responses (50 sweeps) are shown. (**D**) E2-treatment significantly decreased the paired-pulse ratio (P2/P1; indicating that there was a higher probability of glutamate release from Kiss1^Cre:GFP^-ChR2 neurons (Unpaired t-test, t~(20)~ = 4.184, p\<0.001). (**E**) similarly using a paired-pulse regime, fast glutamatergic inward currents were recorded in NPY^GFP^ neurons (V~hold~ = −60 mV) from both oil-treated, OVX (upper trace, black) and E2-treated, OVX (lower trace, red) females. The averaged responses (50 sweeps) are shown. (**F**) E2-treatment significantly decreased the paired-pulse ratio (P2/P1) indicating that there was a higher probability of glutamate release from Kiss1^Cre:GFP^-ChR2 neurons (Unpaired t-test, t~(14)~ = 3.255, p\<0.01). \*\*p\<0.01, \*\*\*p\<0.001.\
10.7554/eLife.35656.010Figure 5---source data 1.The paired-pulse ratio (P2/P1) for [Figure 5D and F](#fig5){ref-type="fig"}.](elife-35656-fig5){#fig5}

Previously, we found that Kiss1^ARH^ neurons send projections to and excite Kiss1^AVPV/PeN^ neurons via glutamate release ([@bib61]). Currently we confirmed that ChR2-mCherry injections labeled Kiss1^ARH^ neurons within the arcuate nucleus only ([Figure 6A1](#fig6){ref-type="fig"}), and sent extensive fiber-projections rostrally to the AVPV/PeN area in the vicinity of immunoreactive Kiss1 neurons ([Figure 6A2,A3](#fig6){ref-type="fig"}). Notably, ChR2-mCherry expressing cell bodies were not found in the AVPV/PeN. Thus, we determined whether this glutamatergic projection was also regulated by E2. We used a coronal slice preparation that contained only the ARH *Kiss1^Cre:GFP^*-AAV1-DIO-ChR2:mCherry (or ChR2:YFP) fiber projections to the AVPV/PeN ([Figure 6A2,A3](#fig6){ref-type="fig"}) and explored the light-evoked glutamate release from Kiss1^ARH^ neurons ([Figure 6B](#fig6){ref-type="fig"}). Photostimulation-induced an inward current in Kiss1^AVPV/PeN^ neurons, which was blocked in the presence of TTX (1 μM) but rescued with addition of 4-AP in the presence of TTX (n = 4) ([Figure 6C](#fig6){ref-type="fig"}). Therefore, this is biophysical evidence for direct synaptic signaling from Kiss1^ARH^ neurons to Kiss1^AVPV/PeN^ neurons. Using a photoactivation-PPR protocol of two 5 ms LED stimulations as described above, we found that AVPV/PeN neurons, including Kiss1^AVPV/PeN^ neurons, from E2-treated females had reduced PPR, an indication that Kiss1^AVPV/PeN^ neurons, similar to POMC and NPY/AgRP neurons, receive an enhanced glutamatergic input from Kiss1^ARH^ neurons in E2-treated females ([Figure 6D,E](#fig6){ref-type="fig"}).

![E2 treatment increases the probability of glutamate release from Kiss1^ARH^ neurons onto Kiss1^AVPV/PeN^ neurons.\
(**A1-A2**) Photomicrographs showing the pronounced projections of ChR2:mCherry fibers to the preoptic area including the PeN following bilateral injections of AAV1-DIO-ChR2:mCherry in the ARH of Kiss1^CreGFP^ V2 mice (note that the GFP was not visible in the V2 animals). Therefore, some POA sections from the same animals were stained for kisspeptin using the Caraty 564 antibody and revealed immunoreactive Kiss1 neurons in the PeN (green cells) (**A3**). Essentially none of the POA somas including the Kiss1 cells expressed ChR2-mCherry. Scale bars = 100 µM (**A1,A2**); 50 μm (**A3**). (**B**) schematic of photostimulation of the terminals of Kiss1^ARH^ neurons and recording of Kiss1^AVPV/PeN^ neurons. (**C**) following AAV1-DIO-ChR2:YFP (or mCherry) injection into the ARH, a fast inward current was recorded in Kiss1^AVPV/PeN^ neurons following blue light stimulation (green trace). The response was antagonized by CNQX (10 µM) and AP5 (50 µM) (not shown) and was abrogated in the presence of TTX (1 µM, black trace) but rescued with the addition of the K^+^ channel blocker 4-AP (100 µM, magenta trace; n = 4 neurons). (**D**) using a paired-pulse regime (two blue light pulses of 5 ms duration separated by 50 ms), fast glutamatergic inward currents were recorded in Kiss1^AVPV/PeN^ neurons (V~hold~ = −60 mV) from both oil-treated, OVX (upper trace, black) and E2-treated, OVX (lower trace, red) females. The averaged responses (50 sweeps) are shown. (**E**) E2-treatment significantly decreased the paired-pulse ratio (P2/P1) indicating that there was a higher probability of glutamate release from arcuate Kiss1^Cre:ChR2^ neurons (Unpaired t-test, t~(14)~ = 4.748, p\<0.001). \*\*\*p\<0.001. Inset shows scRT-PCR *post hoc* identification of representative recorded Kiss1^AVPV/PeN^ neurons. RC, recorded cell; +, positive control (with reverse transcriptase); -, negative control (without reverse transcriptase); MM, molecular marker.\
10.7554/eLife.35656.012Figure 6---source data 1.The paired-pulse ratio (P2/P1) for [Figure 6E](#fig6){ref-type="fig"}.](elife-35656-fig6){#fig6}

High frequency stimulation of glutamate release from Kiss1^ARH^ neurons excites POMC neurons and inhibits NPY neurons via metabotropic receptors {#s2-5}
------------------------------------------------------------------------------------------------------------------------------------------------

Although optogenetic activation of Kiss1^ARH^ neurons at low frequency caused similar ionotropic stimulation of both POMC and NPY/AgRP neurons, high-frequency stimulation of Kiss1^ARH^ neurons/fibers, while blocking the fast AMPA/NMDA input with CNQX + AP5, had differential actions on these two different populations of ARH neurons as measured in slices from E2-treated females. High-frequency (20 Hz) stimulation of Kiss1^ARH^ neurons/fibers generated a slow EPSC in POMC^EGFP^ neurons, and in current clamp the stimulation depolarized POMC neurons and increased their firing rate ([Figure 7A--C](#fig7){ref-type="fig"}). In contrast, high-frequency optogenetic stimulation generated a slow IPSC in NPY^GFP^ neurons, and in current clamp the same stimulus hyperpolarized and inhibited NPY neurons ([Figure 7A,D,E](#fig7){ref-type="fig"}). This high frequency response was blocked approximately 90% by the mGluR7 antagonist ADX71743 (IPSP reduced from 5.9 ± 1.2 mV to 0.6 ± 0.2 mV, n = 5; paired t-test, t~(4)~ = 4.281, p=0.013). The change in membrane potential following Kiss1^ARH^ stimulation was significantly different between POMC and NPY/AgRP neurons ([Figure 7F](#fig7){ref-type="fig"}). Therefore, high-frequency activity in Kiss1^ARH^ neurons, which through presumably glutamate spillover to extrasynaptic mGluRs ([@bib47]; [@bib82]), excites POMC but inhibits NPY/AgRP neurons.

![High frequency stimulation of Kiss1^Cre:GFP^ neurons inhibits NPY neurons but excites POMC neurons.\
(**A**) Schematic of photostimulation of the terminals of Kiss1^ARH^ neurons and recording of POMC or NPY/AgRP neurons. (**B**) high-frequency optogenetic stimulation (20 Hz, 10 s) of Kiss1^Cre:GFP^ neurons/fibers, which were labeled with AAV-DIO-ChR2-mCherry, generated a slow EPSC in POMC^EGFP^ neurons (in the presence of CNQX, 10 μM and AP5, 50 μM). (**C**) in current clamp the same stimulus depolarized and increased the firing frequency of POMC neurons. (**D**) in voltage clamp (V~hold~ = −60 mV) high-frequency stimulation of Kiss1^Cre:GFP^-ChR2 neurons/fibers generated a slow IPSC in NPY^GFP^ neurons (CNQX, 10 μM; AP5, 50 μM). (**E**) in current clamp the same stimulus hyperpolarized and inhibited the firing frequency of NPY neurons. (**F**) summary of the effects of high-frequency stimulation of Kiss1^Cre:GFP^-ChR2 neurons on POMC neurons (depolarized 9.5 ± 1.5 mV, n = 7) and on NPY neurons (hyperpolarized 6.4 ± 1.4 mV, n = 6). The responses (change in membrane potential, Delta Vm) were significantly different in POMC versus NPY/AgRP neurons (Unpaired t-test, t ~(11)~=7.685, p\<0.0001). \*\*\*p\<0.001.\
10.7554/eLife.35656.014Figure 7---source data 1.Effects of high-frequency stimulation of Kiss1^Cre:GFP^-ChR2 neurons on POMC and NPY neurons ([Figure 7F](#fig7){ref-type="fig"}).](elife-35656-fig7){#fig7}

Next, we used scRT-PCR to measure the expression of excitatory and inhibitory metabotropic glutamate receptors in individual POMC and NPY/AgRP neurons. This analysis revealed that POMC neurons expressed group I metabotropic glutamate receptor, mGluR1 and/or mGluR5 (mGluR1, 44%, n = 5 animals; mGluR5, 21%, n = 5 animals) ([Figure 8A,B](#fig8){ref-type="fig"}), whereas NPY/AgRP neurons expressed primarily the group III metabotropic glutamate receptors, mGluR7, with a few neurons also expressing the group II mGluR2 (mGluR7, 50%, n = 5 animals; mGluR2, 13%; n = 4 animals) ([Figure 8C,D](#fig8){ref-type="fig"}). Therefore, we used the mGluR 1/5 agonist DHPG (3,5-dihydroxyphenylglycine) to explore its action in POMC neurons, and found that DHPG (50 μM) depolarized and stimulated firing in POMC neurons ([Figure 9A](#fig9){ref-type="fig"}), and induced an inward current in synaptically-isolated POMC neurons ([Figure 9B](#fig9){ref-type="fig"}). The I-V relationship for the DHPG-induced current showed a reversal at −30 mV ([Figure 9C](#fig9){ref-type="fig"}), indicating that a cationic current was driving the pronounced depolarization. However, there was no difference in the depolarizing effects of DHPG on POMC neurons in oil-treated as compared to E2-treated, OVX females ([Figure 9D](#fig9){ref-type="fig"}). Confirming the scRT-PCR findings, DHPG had no effect on NPY/AgRP neurons (data not shown).

![Metabotropic glutamate receptor expression in POMC and NPY neurons.\
(**A**) representative gels illustrating mRNA expression of *Pomc*, *Grm1* (encoding mGluR1) and *Grm5* (encoding mGluR5) in individual POMC^EGFP^ neurons. The expected base pair (bp) sizes for *Pomc*, *Grm1* and *Grm5* are 200 bp, 186 bp, 247 bp, respectively. (**B**) bar graphs summarizing the percentage (mean ±SEM) of POMC^EGFP^ cells (24 cells each from 5 animals) that expressed *Pomc*, *Grm1*, and *Grm5 mRNAs*. (**C**) representative gels illustrating mRNA expression of NPY, *Grm2 (encoding* mGlur2) and *Grm7 (encoding* mGlur7) in individual NPY^GFP^ neurons. The expected base pair (bp) sizes for *Npy*, *Grm2* and *Grm7* are 182 bp, 145 bp, 109 bp, respectively. (**A,C**) exclusion of reverse transcriptase (-RT) in a reacted cell was used as negative control. RNA extracted from medial basal hypothalamic tissue was also included as positive (+, with RT) and negative (-, without RT) tissue controls. (**D**) bar graphs summarizing the percentage (mean ± SEM) of NPY^GFP^ cells (24 cells each from 5 animals) that expressed *Npy*, *Grm2*, and *Grm7* mRNAs.\
10.7554/eLife.35656.016Figure 8---source data 1.*Pomc, Grm1 and Grm5* mRNA expression in POMC neurons ([Figure 8B](#fig8){ref-type="fig"}).*Npy Grm2 and Grm7* mRNA expression in NPY neruons ([Figure 8D](#fig8){ref-type="fig"}).](elife-35656-fig8){#fig8}

![Metabotropic glutamate response is excitatory in POMC neurons.\
(**A**) metabotropic glutamate receptor 1/5 agonist DHPG (50 µM) depolarized and induced firing of a POMC neuron. (**B**) Rapid bath application of DHPG induced an inward current in the presence of fast sodium channel and ionotropic glutamatergic blockade, V~hold~ = −60 mV. (**C**) voltage ramps from 0 to −100 mV were applied (over 2 s) before and during the treatment with DHPG, showed a reversal at −30 mV. (**D**) summary of the depolarizing effects of DHPG in POMC neurons in oil-treated and E2-treated, OVX females. There was not a significant difference in the response (Unpaired t-test, t~(13)~ = 0.4168, p=0.6831).\
10.7554/eLife.35656.018Figure 9---source data 1.Depolarizing effects of DHPG in POMC neurons in oil-treated and E2-treated, ovariectomized females ([Figure 9D](#fig9){ref-type="fig"}).](elife-35656-fig9){#fig9}

To pharmacologically elucidate the postsynaptic metabotropic glutamate response in NPY neurons, we first utilized the group II mGluR agonist DCG-IV (10 µM), and found that it hyperpolarized and inhibited firing in NPY neurons ([Figure 10A](#fig10){ref-type="fig"}). In addition, DCG-IV in the presence of fast sodium channel, ionotropic glutamatergic and GABAergic blockade induced an outward current in NPY/AgRP neurons ([Figure 10B](#fig10){ref-type="fig"}). The I-V relationship for the DCG-IV induced current exhibited inward rectification and a reversal potential at E~K~^+^ (−95 mV), the hallmark of activation of G protein-coupled inwardly rectifying K^+^ (GIRK) channels ([Figure 10C](#fig10){ref-type="fig"}). Moreover, 10 µM DCG-IV was more efficacious to hyperpolarize NPY/AgRP neurons in E2-treated OVX females, indicating that there was a more robust E2-induced inhibition of NPY/AgRP neurons ([Figure 10G](#fig10){ref-type="fig"}). DCG IV, however, had no effect on POMC neuronal excitability (data not shown). Since mGluR7 was the most highly expressed in NPY/AgRP neurons ([Figure 8](#fig8){ref-type="fig"}), we also tested the mGluR7-selective agonist AMN082 (10 µM) ([@bib64]) for its postsynaptic actions on NPY/AgRP neurons. Indeed, AMN082 hyperpolarized and inhibited firing in NPY/AgRP neurons ([Figure 10D](#fig10){ref-type="fig"}). It generated about a 2-fold greater outward current than DCG-IV, which reversed near E~K~^+^ ([Figure 10E,F](#fig10){ref-type="fig"}), and the magnitude of the hyperpolarization was significantly increased in E2-treated, OVX females ([Figure 10H](#fig10){ref-type="fig"}). However, AMN082 (10 µM) had no effect on a POMC neuron that exhibited a robust response to DHPG (data not shown). In addition, the mRNA expression of mGluR7 was significantly increased in NPY neurons obtained from E2- versus oil-treated OVX females ([Figure 10I](#fig10){ref-type="fig"}). Therefore, E2 significantly increases the receptor expression and response of NPY/AgRP to group II/III mGluR's (Gi,o-coupled), which would contribute to the inhibition of these orexigenic neurons in heightened E2-driven reproductive states.

![Metabotropic glutamate response is inhibitory in NPY neurons and augmented by E2.\
(**A**) the group II mGluR agonist DCG-IV (10 µM) hyperpolarized a NPY^GFP^ neuron. (**B**) DCG-IV activated an outward current in a NPY^GFP^ neuron in the presence of fast sodium channel (TTX, 0.5 μM), ionotropic glutamatergic (CNQX, 10 μM and AP5, 50 μM) and GABAergic (picrotoxin, 100 μM) blockers (V ~hold~ = −60 mV). (**C**) I-V relationship for DCG-IV- induced current showed a reversal at E~K+~ (−95 mV). (**G**) DCG-IV was more efficacious to hyperpolarize NPY neurons in E2-treated versus oil-treated, OVX females (Unpaired *t*-test, *t*~(32)~ = 2.261, p=0.031). \*p\<0.05. (**D**) the mGluR7 allosteric agonist AMN082 (10 µM) hyperpolarized and inhibited firing of an NPY^GFP^ neuron. (**E**) AMN082 generated a 25 pA outward current in a NPY^GFP^ neuron in the presence of fast sodium channel and ionotropic glutamatergic blockade (V ~hold~ = −60 mV). (**F**) I-V relationship for AMN082-induced current showed a reversal close to E~K+~. (**H**) AMN082 was more efficacious than DCG-IV to hyperpolarize NPY neurons in E2-treated versus oil-treated, OVX females (Unpaired *t*-test, *t*~(17)~ = 3.747, p=0.002). (**I**) Quantitative real-time PCR measurements of *Grm7* mRNA in NPY^GFP^ neuronal pools (4 pools of 5 cells each per animal) from oil- and E2-treated, OVX mice (n = 4--5 animals per group). Bar graphs represent the mean ± SEM (Unpaired *t*-test, t~(7)~=6.020, p=0.0005). \*\*\*p\<0.001.\
10.7554/eLife.35656.020Figure 10---source data 1.DCG-IV was more efficacious to hyperpolarize NPY neurons in E2-treated versus oil-treated, OVX females ([Figure 10G](#fig10){ref-type="fig"}).AMN082 was more efficacious than DCG-IV to hyperpolarize NPY neurons in E2-treated versus oil-treated ([Figure 10H](#fig10){ref-type="fig"}). *Grm7* mRNA expression in NPY neurons ([Figure 10I](#fig10){ref-type="fig"}).](elife-35656-fig10){#fig10}

Conditional knockout of vGluT2 in Kiss1^ARH^ neurons eliminates glutamate release {#s2-6}
---------------------------------------------------------------------------------

To better understand the function of glutamate in Kiss1 neurons, we ablated vGluT2 specifically in Kiss1 neurons. Given that *Slc17a6* is not expressed in Kiss1^AVPV/PeN^ neurons in our mouse model, this ablation was specific for Kiss1^ARH^ neurons and, perhaps, for other Kiss1 neurons not yet shown to express *Slc17a6,* including the amygdala and bed nucleus of stria terminalis (BNST) Kiss1 neurons ([@bib38]; [@bib61]). To delete vGlut2 from Kiss1 neurons we crossed *Slc17a6^lox/lox^* mice with *Slc17a6^+/∆^::Kiss1^CreGFP/+^* mice, which yielded mice that were knockout (KO) or heterozygotes for *Slc17a6* (Het) in Kiss1 neurons, as well as *Slc17a6* Het and wild-type (WT) mice that lacked Cre. We confirmed the *Slc17a6* deletion in KO mice using scRT-PCR of harvested Kiss1^ARH^ neurons ([Figure 11A](#fig11){ref-type="fig"}). For identification of Kiss1^ARH^ neurons in E2-treated animals and for functional studies, AAV1-DIO-ChR2:YFP was injected bilaterally in the ARH of *Slc17a6* KO, *Slc17a6* Het and control Kiss1^Cre:GFP^ females. Importantly based on the scRT-PCR analysis, none of the YFP cells in KO females expressed *Slc17a6*, whereas 100% expressed *Tac2* ([Figure 11A](#fig11){ref-type="fig"}). The majority of cells also expressed *Kiss1* mRNA, although this transcript was more difficult to detect in E2-treated females (see [Figure 1](#fig1){ref-type="fig"}).

![Deletion of *Slc17a6* in Kiss1^ARH^ neurons attenuates the slow EPSP in Kiss1^ARH^ neurons from E2-treated mice.\
(**A**) representative gels illustrating mRNA expression of *Slc17a6*, *Kiss1* and *Tac2* in *Slc17a6* KO Kiss1^ARH^ neurons and in control Kiss1^ARH^ cells. The expected base pair (bp) sizes for *Slc17a6*, *Kiss1* and *Tac2* are 194, 120 and 147 bp, respectively. RNA extracted from the medial basal hypothalamic tissue was used as positive (+, with RT) and negative (-, without RT) tissue controls. MM, molecular marker. (**B**) Experimental protocol: AAV1-DIO-ChR2:mCherry was bilaterally injected into ARH of Kiss1^Cre:GFP^ control and *Slc17a6* KO mice, followed by high-frequency photostimulation of Kiss1^ARH^ neurons/terminals and recording of Kiss1^ARH^ neurons. (**C**) high-frequency optogenetic stimulation (20 Hz, 10 s) generated a slow EPSP in an arcuate Kiss1^Cre:GFP^ neuron from OVX, control Kiss1 mice. (**D**), high-frequency response (slow EPSP) in arcuate Kiss1^Cre:GFP^ neurons from OVX, Kiss1^Cre:GFP^::Slc17a6^lox/∆^ (KO) mice.(**E**) high-frequency response (slow EPSP) in arcuate Kiss1^Cre:GFP^ neuron from E2-treated, OVX control Kiss1 mice. Inset shows full amplification of sEPSP. (**F**) high-frequency response in arcuate Kiss1^Cre:GFP^ neuron from E2-treated, OVX Kiss1^Cre:GFP^::Slc17a6^lox/∆^ mice. Inset shows full amplification of sEPSP. (**G**) summary of the effects of vGluT2 deletion on slow EPSP amplitude: (one-way ANOVA, effect of treatment, F~(3,\ 50)~=14.13, p\<0.0001; Newman-Keuls' Multiple-comparison test, \*\*\* or ^\#\#\#^, indicates p\<0.005). Although knockout of vGluT2 did not significantly diminish the slow EPSP amplitude in OVX females, it did attenuate the response in E2-treated, OVX females (Unpaired t-test, t ~(25)~=2.735, p=0.0113). a-a, p\<0.05.\
10.7554/eLife.35656.022Figure 11---source data 1.Data for [Figure 11G](#fig11){ref-type="fig"}.](elife-35656-fig11){#fig11}

Based on previous findings, the slow EPSP underlying Kiss1^ARH^ neuronal synchronization, is dependent on the release of Tac2 and dynorphin in Kiss1^ARH^ neurons ([@bib61]). To explore a potential role of glutamate in this function, we generated a slow EPSP using high-frequency (20 Hz, 10 s) optogenetic stimulation in slices obtained from oil- and E2-treated, OVX females ([@bib61]). High-frequency optogenetic stimulation generated a similar slow EPSP amplitude in arcuate Kiss1 neurons from oil-treated, OVX Kiss1 control and oil-treated OVX *Slc17a6* KO Kiss1 mice ([Figure 11C,D,G](#fig11){ref-type="fig"}). In contrast, high-frequency optogenetic stimulation of Kiss1 neurons in E2-treated, OVX control and E2-treated, OVX *Slc17a6* KO mice revealed a significantly reduced slow EPSP in *Slc17a6* KO as compared to control Kiss1^ARH^ neurons ([Figure 11E,F,G](#fig11){ref-type="fig"}). Therefore even though the slow EPSP is generated mainly by Tac2 in OVX females ([@bib61]), glutamate may contribute to the slow EPSP in Kiss1^ARH^ neurons in E2-treated, OVX females.

Deletion of *Slc17a6* in Kiss1 neurons abrogates fast glutamatergic responses in Kiss1^AVPV/PeN^, NPY and POMC neurons {#s2-7}
----------------------------------------------------------------------------------------------------------------------

As described above, low-frequency (0.5 Hz) stimulation of Kiss1^Cre:^ChR2 neurons/fibers activates POMC, NPY/AgRP and Kiss1^AVPV/PeN^ neurons via direct ionotropic glutamatergic input from Kiss1^ARH^ neurons ([Figures 4](#fig4){ref-type="fig"}, [5](#fig5){ref-type="fig"}, [6](#fig6){ref-type="fig"} and [12](#fig12){ref-type="fig"}). Therefore, we used whole-cell, voltage-clamp recordings in Kiss1^AVPV/PeN^, POMC and NPY/AgRP neurons from female *Kiss1^CreGFP^::Slc17a6^lox/∆^* mice and found that low-frequency optogenetic stimulation (0.5 Hz) failed to evoke a fast glutamatergic postsynaptic response in Kiss1^AVPV/PeN^ neurons ([Figure 12C](#fig12){ref-type="fig"}), POMC neurons ([Figure 12E](#fig12){ref-type="fig"}) or NPY/AgRP neurons ([Figure 12G](#fig12){ref-type="fig"}). Interestingly, high-frequency stimulation (20 Hz, 10 s) still evoked a small residual inward current (2.8 ± 0.3 pA, n = 7) in POMC neurons (identified *post hoc* by scRT-PCR, inset) from E2-treated, OVX KO females ([Figure 12H,I](#fig12){ref-type="fig"} versus 7B,F). Likewise, high-frequency stimulation (20 Hz, 10 s) evoked a small outward current (4.0 ± 1.6 pA, n = 4) in NPY/AgRP neurons (identified *post hoc* by scRT-PCR, inset) from E2-treated, KO females ([Figure 12H,J](#fig12){ref-type="fig"} versus 7D,F). Although, selective peptidergic inhibitors for potentially blocking kisspeptin-mediated responses in NPY/AgRP and POMC neurons are not available, we suspect, based on previous findings ([@bib27]), that these evoked postsynaptic responses were generated by kisspeptin release following high-frequency stimulation of Kiss1^ARH^ neurons.

![Deletion of Slc17a6 in Kiss1^ARH^ neurons abrogates fast glutamatergic responses in Kiss1^AVPV/PeN^, POMC and NPY/AgRP neurons.\
(**A**) Experimental protocol: AAV1-DIO-ChR2:mCherry (or YFP) was bilaterally injected into ARH of Kiss1^Cre:GFP^ mice. Thereafter, low-frequency photostimulation of the terminals of Kiss1^ARH^ neurons were done, and postsynaptic responses in Kiss1^AVPV/PeN^, POMC or NPY/AgRP neurons were recorded. (**B,C**) whole-cell, voltage clamp (V~hold~ = −60 mV) recordings in Kiss1^AVPV/PeN^ neurons show that low-frequency optogenetic stimulation (0.5 Hz) evoked fast glutamatergic postsynaptic responses in control female Kiss1^Cre^ mice (**B**, red trace), but failed in Kiss1^AVPV/PeN^ cells (n = 10) from Kiss1^Cre:GFP^::Slc17a6^lox/∆^ mice (**C**, black trace). (**D,E**) and **F,G**) similarly, the response could be induced in POMC neurons (**D**, yellow trace) or NPY/AgRP neurons (**F**, green trace) from control Kiss1^Cre:GFP^ mice, but abrogated in POMC neurons (**E**, black trace) (n = 28) or NPY/AgRP neurons (**G**, black trace) (n = 30) from Kiss1^Cre:GFP^::Slc17a6^lox/∆^ mice. (**H**) Experimental protocol: high-frequency photostimulation of the terminals of Kiss1^ARH^ neurons and recording of POMC or NPY/AgRP neurons. (**I**) high-frequency stimulation (20 Hz, 10 s) of arcuate Kiss1 neurons from Kiss1^Cre:GFP^::Slc17a6^lox/∆^ mice evoked a small inward current (2.8 ± 0.5 pA, n = 7) in POMC neurons (identified *post hoc* by scRT-PCR, gel inset). (**J**) likewise, high-frequency stimulation evoked a small outward current (4.0 ± 1.6 pA, n = 4) in NPY/AgRP neurons (identified *post hoc* by scRT-PCR, gel inset). Insets show scRT-PCR *post hoc* identification of representative recorded POMC and NPY neurons. RC, recorded cells; +, positive tissue control reacted with RT; -, negative tissue control reacted without RT; MM, molecular marker.](elife-35656-fig12){#fig12}

To further study the actions of kisspeptin on NPY/AgRP and POMC neurons, we applied kisspeptin directly on these neurons. Kisspeptin (200 nM) inhibited firing and hyperpolarized NPY^GFP^ neurons even in the presence of the GABA~A~ blocker bicuculline (10 μM) ([Figure 13A,B](#fig13){ref-type="fig"}). Also, similar to the GABA~B~ receptor agonist baclofen, kisspeptin induced an outward, albeit smaller current with a reversal potential close to E~K~^+^ (−90 mV) ([Figure 13C](#fig13){ref-type="fig"}). In addition to binding to the Kiss1 receptor (GPR54), kisspeptin is also known to bind to and activate neuropeptide FF receptors 1 and 2 (NPFFR1 and NPFFR2), and these Gαi/o coupled receptors are both expressed in the ARH ([@bib22]; [@bib62]). We used scRT-PCR to document the expression of *Npffr1* mRNA in NPY neurons ([Figure 13D](#fig13){ref-type="fig"}). Finally, the RFamide-related peptide-3 (RFRP-3) (10 μM), a selective agonist for NPFFR1 and NPFFR2 ([@bib7]), hyperpolarized and inhibited the firing of NPY/AgRP neurons ([Figure 13E](#fig13){ref-type="fig"}). The I/V plot of the RFRP-3 induced current showed a reversal potential close to E~K~^+^ (−85 mV) ([Figure 13F](#fig13){ref-type="fig"}). Therefore, it is probable that kisspeptin and RFRP3 activate the same receptor on NPY/AgRP neurons.

![Kisspeptin and RFRP-3 inhibit NPY neurons.\
(**A,B**) kisspeptin (200 nM) inhibited the firing and hyperpolarized NPY neurons even in the presence of GABA~A~ blocker bicuculline (BIC) (10 μM). (**C**) Similar to GABA~B~ receptor agonist baclofen (10 μM), kisspeptin induced an outward, albeit smaller, current with a reversal potential at E~K+~ (−90 mV). (**D**) scRT-PCR expression of *Npffr1* in NPY/AgRP neurons. (**E**) RFRP-3 (10 μM), selective agonist for NPFFR1/NPFFR2, hyperpolarized and inhibited firing in NPY neurons. (**F**) the I/V plots of the RFRP-3 current showed a reversal potential close to E~K+~ (−85 mV).](elife-35656-fig13){#fig13}

We also explored the actions of kisspeptin on POMC neurons after first identifying that *Kiss1r* mRNA (GPR54) is expressed in a subpopulation of these neurons using scRT-PCR ([Figure 14A](#fig14){ref-type="fig"}). In agreement with a previous publication ([@bib27]), we found that kisspeptin (200 nM) depolarized and increased the firing frequency of POMC neurons ([Figure 14B](#fig14){ref-type="fig"}). In addition, the I/V plot showed that kisspeptin activated a non-selective cationic channel that reversed at −10 mV ([Figure 14C](#fig14){ref-type="fig"}).

![Kisspeptin excites POMC neurons by activating a non-selective cation conductance.\
(**A**) representative gel illustrating the scRT-PCR expression of *Kiss1r* (GPR54) transcript in POMC neurons. (**B**) kisspeptin (200 nM) depolarized and increased firing of POMC neurons (n = 8). (**C**) I/V (digital subtraction of control I/V from I/V with kisspeptin using a Cs^+^-based internal solution; see Materials and Methods) showed that kisspeptin activated a non-selective cationic channel that reversed at −10 mV.](elife-35656-fig14){#fig14}

Female mice lacking *Slc17a6* in Kiss1 neurons develop a condition place preference for sucrose {#s2-8}
-----------------------------------------------------------------------------------------------

*Ad libitum* access to standard, low-fat mouse chow did not affect body weight in mice lacking *Slc17a6* in Kiss1 neurons versus control females over the limited time-course of our study (data not shown). Therefore, we hypothesized that the lack of glutamate release from Kiss1^ARH^ neurons might increase motivation for palatable food in *Slc17a6* KO females due to diminished regulatory synaptic input onto POMC, NPY/AgRP neurons or other target neurons. For this analysis we used a conditioned place preference (CPP) paradigm ([Figure 15](#fig15){ref-type="fig"}), that has been used extensively to evaluate drugs of abuse as well as the preference for palatable food ([@bib18]; [@bib32]; [@bib57]; [@bib69]). While several groups have used sucrose pellets/solutions to produce a CPP ([@bib1]; [@bib20]; [@bib52]) many investigators have found food restriction as a necessary adjuvant ([@bib5]; [@bib25]). However, even with short-term food deprivation, homeostatic processes can be engaged that prevent selective study of hedonic pathways, as evidenced by the ability of standard chow to produce a CPP following 20 h/day of food restriction ([@bib52]; [@bib56]). Therefore, to study hedonic feeding, we used *ad-libitum* fed mice and tested them during the dark phase when mice normally eat most of their food.

![Protocol for inducing CPP with sucrose.\
The protocol for conditioning and preference testing consisted of four phases over the course of 11 days (sucrose habituation, a baseline place preference (BPP) test, sucrose conditioning, and a conditioned place preference (CPP) test). Food-motivated behavior was assessed during the dark cycle using an unbiased procedure. On the day before BPP, Day −1, sucrose habituation occurred where mice received sucrose pellets overnight (O/N) in their home cage to prevent neophobia. The initial BPP (black vs. white chamber) was assessed on Day 1 in a three-chamber place preference apparatus and the chamber pairing was assigned in an unbiased manner. During sucrose conditioning, mice were given access to sucrose-filled (CS+, Days 2, 4, 6, 8) or empty (CS-, Days 3, 5, 7, 9) lids on alternating days. Mice were given access to sucrose-filled lids in one chamber (e.g. white), then on alternating days they were presented with empty lids in the other chamber (e.g. black). Mice were tested for acquisition of a CPP to sucrose on Day 10, which was indicated by increased time spent in the sucrose-conditioned chamber. Animals were fed *ad lib* standard low-fat chow in their home cage throughout the study. For cyclical estradiol treatment, animals were given a priming (0.25 μg) and a surge (1.5 μg) dose of 17β-estradiol Benzoate (E2) at 9 AM prior to the BPP and prior to the CPP as indicated. During the sucrose-conditioning (phase 3), the animals were treated twice with a 1 μg maintenance dose of E2.](elife-35656-fig15){#fig15}

Food-motivated, behavioral analysis revealed that E2-treated, OVX Kiss1 female mice failed to exhibit a change in place preference for sucrose, a natural food reward ([Figure 16A](#fig16){ref-type="fig"}, [Figure 16---figure supplement 1](#fig16){ref-type="fig"}). In contrast, E2-treated, OVX *Slc17a6* KO mice significantly increased their occupancy of the sucrose-paired chamber ([Figure 16A](#fig16){ref-type="fig"}). E2-treated, OVX Heterozygous (*Slc17a6^+/lox^::Kiss1^CreGFP/+^*) mice showed a trend to increase their occupancy in the sucrose-paired chamber ([Figure 16A](#fig16){ref-type="fig"}). In addition, we measured the amount of sucrose consumed by each experimental group during conditioning. The E2-treated, OVX Kiss1 controls did not increase their sucrose intake at any time ([Figure 16B](#fig16){ref-type="fig"}, [Figure 16---figure supplement 1](#fig16){ref-type="fig"}). The *Slc17a6* KO females slightly increased their sucrose intake on day 6 of the test (third day of sucrose exposure; [Figure 15](#fig15){ref-type="fig"}) and this was significantly augmented by day 8 of the test (fourth day of sucrose exposure) ([Figure 16B](#fig16){ref-type="fig"}, [Figure 15](#fig15){ref-type="fig"}). The *Slc17a6* Het mice exhibited a smaller, but significant increase in sucrose consumption on day 6 of the test ([Figure 16B](#fig16){ref-type="fig"}). Together, these findings indicate that E2-treated, OVX Kiss1 control females had a consistent diminished motivation for sucrose, whereas abolishing glutamate release from Kiss1 neurons enhanced the motivational response for sucrose. Interestingly, attenuating glutamate release from Kiss1 neurons in *Slc17a6* Het females nearly recapitulated the phenotype of the *Slc17a6* KO animals suggesting a gene-dosage/threshold effect. We also measured the body weight gain over the ten-day period of the CPP test. Although both the *Slc17a6* KO and Het mice gained weight in comparison to the E2-treated, OVX Kiss1 controls, the difference was only statistically significant in the *Slc17a6* Het mice ([Figure 16C](#fig16){ref-type="fig"}). Based on these findings, we measured the mRNA expression of *Slc17a6* in Kiss1^ARH^ neurons in the heterozygous E2-treated, OVX females (*Slc17a6 Het*) as compared to control E2-treated, OVX Kiss1^Cre^ females. As illustrated ([Figure 16D](#fig16){ref-type="fig"}), *Slc17a6* mRNA in Het mice was \~35% of that of controls (*Slc17a6* Het mice, 5 pools each from 4 animals; Kiss1 control mice, 5 pools each from 5 animals), and *Slc17a6* mRNA was not detected in Kiss1 neurons from *Slc17a6* KO females. Interestingly intact males, which have reduced Slc17a6 mRNA expression in Kiss1^ARH^ neurons and reduced glutamate release compared to castrates ([@bib46]) and E2-treated females, demonstrated a motivation for sucrose based on CPP ([Figure 16---figure supplement 1](#fig16){ref-type="fig"}).

![Female mice lacking *Slc17a6* in Kiss1^ARH^ neurons develop a conditioned place preference for sucrose.\
(**A**) Time spent in sucrose-paired chamber by control Kiss1 female mice (n = 8), *Slc17a6* Het (n = 4) and *Slc17a6* KO Kiss1 females (n = 8) was measured during the Pretest (Day 1, Baseline Place Preference) and the Posttest (Day 10, Conditioned Place Preference). All animals were OVX and E2-treated, and had free access to standard mouse chow in their home cage throughout the study. After sucrose conditioning, *Slc17a6* KO mice developed a preference for the sucrose-paired chamber (Bonferroni *post hoc* test, p=0.001). *Slc17a6* Het mice displayed a trend to develop a preference for the sucrose-paired chamber (Bonferroni *post hoc* test, p=0.086). Control Kiss1^Cre^ female mice, however, failed to develop a preference (Bonferroni *post hoc* test, p=0.619). \[Also, see [Figure 16---figure supplement 1A](#fig16s1){ref-type="fig"} for comparison between E2-treated, OVX Kiss1 female and intact Kiss1 male mice\]. Two-way ANOVA: main effect of experimental group (*F~(2,17)~* = 0.298, p=0.746), main effect of protocol day (*F~(1,17)~* = 20.34, p=0.0003), and interaction (*F~(2,17)~* = 2.33, p=0.128); \*\*p\<0.01.(**B**) Sucrose consumption during the CPP. Sucrose intake (mg) was measured during the four sucrose-paired days (Days 2, 4, 6, and 8). *Slc17a6* KO mice slightly increased their sucrose intake on Day 6 and this was significantly increased by Day 8 (Bonferroni *post hoc* test, p\<0.0001). *Slc17a6* Het mice displayed a smaller, but significant increase in sucrose intake on Day 6 (Bonferroni *post hoc* test, p=0.0464). \[Also, see [Figure 16---figure supplement 1B](#fig16s1){ref-type="fig"} for comparison between E2-treated, OVX Kiss1 females and intact Kiss1 males\]. Two-way ANOVA: main effect of experimental group (*F~(2,17)~* = 3.788, p=0.0436), main effect of protocol day (*F~(3,51)~* = 12.75, p\<0.0001), and interaction (*F~(6,51)~* = 5.763, p\<0.0001). \*p\<0.05, Het mice versus Kiss1 control; \*\*\*p\<0.001, *Slc17a6* KO mice versus Kiss1 control. (**C**) Body weight-gain during the ten-day CPP period. Despite that both the *Slc17a6* KO and Het mice gained weight in comparison to control Kiss1 mice, only *Slc17a6* Het mice were significantly different (Bonferroni *post hoc* test, p=0.0312, *Slc17a6 Het* vs Kiss1 control; p=0.066, *Slc17a6* KO vs Kiss1 control;). One-way ANOVA: main effect of experimental group (*F~(2,17)~* = 5.232, p=0.017). \*p\<0.05, Het mice versus Kiss1 control. (**D**) Quantitative real time PCR measurement of *Slc17a6* in Kiss1^ARH^ neuronal pools from control Kiss1^Cre:GFP^ mice (5 Kiss1 neurons in each pool and 5 pools from each of 5 animals) and *Slc17a6* Het Kiss1 mice (5 Kiss1 neurons in each pool and 5 pools from each of 4 animals). *Slc17a6* KO Kiss1 mice did not express *Slc17a6* in Kiss1^ARH^ neurons. (Unpaired t-test, t~(7)~ = 5.791, p=0.0007). \*\*\*p\<0.001, Het mice versus Kiss1 control.\
10.7554/eLife.35656.030Figure 16---source data 1.CPP Time Spent: Ovx Kiss2 Female Mice (n = 8); Ovx HET Female Mice (n = 4); Ovx KO Female Mice (n = 8) for [Figure 16A](#fig16){ref-type="fig"}.CPP Sucrose intake: Ovx Kiss2 Control Female Mice (n = 8); Ovx HET Female Mice (n = 4); Ovx KO Female Mice (n = 8) for [Figure 16B](#fig16){ref-type="fig"}. CPP Weight Gain (Day 10 Day 1): Ovx Kiss2 Control Female Mice (n = 8); Ovx HET Female Mice (n = 4); Ovx KO Female Mice (n = 8) for [Figure 16C](#fig16){ref-type="fig"}. *Slc17a6* mRNA expression in Kiss1-ARH neurons for [Figure 16D](#fig16){ref-type="fig"}.](elife-35656-fig16){#fig16}

Deletion of *Slc17a6* in Kiss1 neurons does not alter the estrous cycle {#s2-9}
-----------------------------------------------------------------------

We have shown previously and currently that Kiss1^ARH^ neurons exhibit direct communication with Kiss1^AVPV/PeN^ neurons via glutamate, which project to and excite GnRH neurons via kisspeptin release ([@bib61]). Therefore, we hypothesized that glutamate released from Kiss1^ARH^ neurons would be involved in the excitation of Kiss1^AVPV/PeN^ neurons and the induction of the GnRH surge. As a consequence, deletion of *Slc17a6* in Kiss1^ARH^ neurons might lead to disruption of the estrous cycle and the GnRH surge and thus affect fertility. However, we found that the estrous cycle was normal in *Slc17a6 KO* females (one-way ANOVA; p=0.68; comparing cycle length between: wild types (WT), n = 5, 5.55 ± 0.42; Het, n = 3, 4.89 ± 0.48; and KO, n = 7, 5.43 ± 0.44), although the staging of the cycle was not confirmed by steroid hormone measurements. Similarly, the time to conception when placed with a fertile male was not different between the three groups (one-way ANOVA; p=0.68 comparing time (days) to conception between: WT, n = 9, 1.75 ± 0.40; Het, n = 3, 2.83 ± 1.64; KO, n = 8, 1.89 ± 0.67).

Discussion {#s3}
==========

It is well known that the peptide neurotransmitters in Kiss1^ARH^ neurons are negatively regulated by E2, and these neurons are responsible for pulsatile release of GnRH and reproduction ([@bib48]). Our current findings that E2 increases the expression of *Slc17a6* and glutamate release reveal that the amino acid and peptide neurotransmitters are regulated differentially by E2 in Kiss1^ARH^ neurons in females in contrast to our findings in males ([@bib46]). We also found that E2 increased the expression of T-type calcium and h-currents in female Kiss1^ARH^ neurons, which led to increased neuronal excitability, concomitant with E2-induced inhibition of the expression of the peptide neurotransmitter mRNAs *Kiss1*, *Tac2* and *Pdyn*. Optogenetic activation of Kiss1^ARH^ neurons revealed direct frequency-dependent glutamatergic and peptidergic neurotransmission to POMC and AgRP neurons in females, an indication that Kiss1^ARH^ neurons may play a role in regulating feeding behavior. The glutamatergic outputs were lost in females with conditional ablation of *Slc17a6* in Kiss1^ARH^ neurons, whereas excitatory and inhibitory kisspeptin responses could be evoked in POMC and NPY/AgRP neurons, respectively. Experiments in vivo revealed that Slc17a6 KO females did not gain weight on normal mouse chow, but the motivation to ingest sucrose was increased in females lacking vGluT2 in Kiss1 neurons. Overall, these and other findings support the idea that Kiss1^ARH^ neurons may provide E2- and frequency- dependent signals not only to POMC and NPY/AgRP neurons, but also to Kiss1^AVPV/PeN^ neurons to help coordinate feeding and reproduction in females ([Figure 17](#fig17){ref-type="fig"}).

![Working Model. KNDy (Kisspeptin, NKB, Dynorphin) neurons in the ARH express Ca~V~3 (I~T~) and HCN (I~h~) channels (currents) that are upregulated by E2 and contribute to increased excitability of Kiss1^ARH^ neurons.\
Kiss1^AVPV/PeN^ neurons also express Ca~V~3 (I~T~), HCN (I~h~) and Nav (I~NaP~) channels that are highly up-regulated by E2 along with *Kiss1* mRNA expression. Notably, E2 induces spontaneous, repetitive burst firing activity in Kiss1^AVPV/PeN^ neurons necessary for the release of GnRH ([@bib81]; [@bib84]). E2 also directly excites POMC neurons via inhibition of GIRK current, but inhibit NPY/AgRP neurons via activation of GIRK current ([@bib36]). These congruent actions of E2 on POMC and NPY/AgRP neurons contribute to the control of homeostatic feeding. High frequency photo-stimulation (focal light stimulation of channel rhodopsin, ChR2) in Kiss1^ARH^ neurons releases glutamate to further excite POMC neurons via mGluRs group I and inhibit NPY/AgRP neurons via mGluRs group II/III; and excite Kiss1^AVPV/PeN^ neurons via NMDA/AMPA receptors. Ablating *Slc17a6* from Kiss1^ARH^ neurons, results in the abrogation of glutamate release onto POA and ARH neurons. The lack of glutamate release from Kiss1^ARH^ neurons appears to have little or no effect on estrous cyclicity, an indication that the direct effects of E2 to increase the excitability of Kiss1^AVPV/PeN^ neurons is sufficient to drive the reproductive cycle. However, E2-treated *Slc17a6* KO Kiss1 mice develop a condition place preference for sucrose indicative of positive motivational effect of sucrose in these females.](elife-35656-fig17){#fig17}

Kiss1^ARH^ neurons are known to co-express the peptide neurotransmitters Kiss1, Tac2 and Dynorphin ([@bib29]; [@bib38]; [@bib45]). Using sc-qPCR we observed that *Tac2,* and not *Kiss1*, is by far the most highly expressed peptide mRNA in Kiss1^ARH^ neurons. Even in the presence of high physiological levels of E2, the mRNA expression of *Tac2* was many-fold higher than *Kiss1* under the same treatment. Since Tac2 plays a key role in synchronous firing of Kiss1^ARH^ neurons ([@bib61]), which underlies the pulsatility of GnRH release that drives pituitary LH secretion ([@bib13]), it is not surprising that *Tac2* was found to be the most highly expressed peptide in Kiss1^ARH^ neurons.

Given that the peptide neurotransmitters in Kiss1^ARH^ neurons are primarily down-regulated by E2, at least in rodents, the Kiss1^ARH^ neurons are believed to be under inhibitory control by E2 and are important for negative-feedback regulation of GnRH and LH secretion ([@bib38]; [@bib45]; [@bib72]). However, our past ([@bib31]) and current findings that these Kiss1^ARH^ neurons express T-type calcium and pacemaker h-currents and are keenly sensitive to excitation by glutamate are indications that these neurons have pacemaker electrophysiological properties similar to other CNS neurons ([@bib4]; [@bib43]). Additionally, in contrast to the neuropeptides, E2 increased *Slc17a6* mRNA expression in Kiss1^ARH^ neurons and increased glutamate release onto Kiss1^AVPV/PeN^ neurons in the POA, and onto POMC and NPY/AgRP neurons in the ARH. This is a clear indication that the amino acid and peptide neurotransmitters are regulated differentially by E2 in Kiss1^ARH^ neurons in females. Interestingly, we have reported that *Slc17a6* mRNA expression in Kiss1^ARH^ neurons and the probability of glutamate release are decreased along with the neuropeptides in intact versus castrated males ([@bib46]). Therefore, there is a significant male/female difference in sex-steroid regulation of glutamate signaling by Kiss1^ARH^ neurons ([@bib46]). This could underlie the sex differences in feeding behavior between males and females, namely that testosterone increases feeding in castrated males, whereas E2 reduces feeding in OVX females and during the peri-ovulatory phase of the estrous cycle when E2 levels are maximal ([@bib2]; [@bib3]).

The mechanism by which E2 signals in Kiss1^ARH^ neurons to inhibit the expression of neuropeptides appears to be via ERα, given that ablation of ERα in Kiss1^ARH^ neurons prevents E2-induced suppression of *Kiss1* mRNA, and also global KO of ERα prevents suppression of *Tac2* and *Pdyn* by E2 in the ARH ([@bib21]; [@bib83]). The mechanism by which E2 enhances glutamatergic expression and transmission in Kiss1^ARH^ neurons is currently unknown. Potentially, E2 acting via different E2 receptors and/or signaling pathways in Kiss1^ARH^ neurons could be responsible for the diverse actions of E2 (decrease in the expression of neuropeptides versus the increase in expression of excitatory ion channels and glutamate release) similar to what has been reported previously in hippocampal neurons and in hypothalamic NPY/AgRP neurons ([@bib10]; [@bib70],[@bib71]).

The excitatory glutamatergic inputs to NPY/AgRP neurons play a key role in the response to fasting, although the origin of this excitatory input has not been determined ([@bib41]). Similarly, it has been shown that glutamatergic neurons other than POMC neurons within the arcuate nucleus are responsible for a fast acting satiety signal to suppress feeding even after a 24 hr fast in male mice ([@bib24]). In addition, our current findings using optogenetic stimulation of Kiss1^ARH^ neurons in vitro have documented direct excitatory projections to both POMC and NPY/AgRP neurons by low-frequency stimulation, whereas high-frequency stimulation activated POMC and inhibited NPY/AgRP neurons in both males ([@bib46]) and females (current findings). The low-frequency excitation was blocked by TTX, but reinstated by application of the potassium channel blocker 4-AP, which is biophysical evidence of direct synaptic input from Kiss1^ARH^ neurons to POMC and NPY/AGRP neurons in agreement with our previous findings in males ([@bib46]). High-frequency optogenetic stimulation (20 Hz) of Kiss1^ARH^ neurons, which mimics a firing rate that is observed in these ARH neurons in vivo ([@bib44]), excited POMC neurons. This appears to be generated by an activation of group I metabotropic glutamate receptors 1 and 5, both of which we have documented are expressed in POMC neurons. Also, we found that the group I mGluR agonist DHPG excited POMC neurons in the presence of TTX and ionotropic glutamate receptor blockers. Collectively these data demonstrate that there is a direct excitatory input to POMC neurons from Kiss1^ARH^ neurons via glutamate actions on ionotropic and metabotropic receptors. In contrast, we found that high-frequency stimulation generated an inhibition of NPY/AgRP neurons, which was mediated by glutamatergic type II/III metabotropic receptors. Indeed, we found that NPY/AgRP neurons express *Grm7* mRNA (encoding mGluR7), and to a lesser extent *Grm2* mRNA (encoding mGluR2) and that the high frequency response was inhibited by the mGluR7 antagonist ADX71743. In addition, these neurons were inhibited by bath application of the group II mGluR agonist DCG-IV and the group III mGluR agonist AMN082 in the presence of synaptic blockade by TTX, and ionotropic glutamate and GABA~A~ inhibitors, providing evidence for a direct inhibitory Kiss1^ARH^ glutamatergic input to NPY/AgRP neurons. The response in POMC neurons to group I metabotropic agonist DHPG, which activates a TRPC current ([@bib77]), was not different between oil- and E2-treated, OVX females. In contrast, the GIRK current in NPY/AgRP neurons, which was activated by the group II and the group III metabotropic glutamate receptor agonists, was augmented by E2-treatment, as was the mRNA expression of mGluR7. Congruent with these findings, we have shown that E2-treatment increases KCNQ 5 channel expression and the corresponding inhibitory M-current in NPY/AgRP neurons ([@bib66]) and augments postsynaptic GABA~B~ receptor coupling ( [@bib70], [@bib71]). Clearly, E2 inhibits the orexigenic NPY/AgRP neurons via multiple mechanisms and thereby helps to prevent hyperphagia ([@bib65]).

The evidence that Kiss1^ARH^ neurons are involved in the regulation of GnRH and LH pulsatility via their peptide neurotransmitters is well documented ([@bib13]; [@bib28]; [@bib45]; [@bib61]; [@bib79]). Although it is known that *Slc17a6* is expressed in Kiss1^ARH^ neurons ([@bib16]; [@bib46]), the role of glutamate neurotransmission from these neurons had not been elucidated. Currently, we deleted vGluT2 (*Slc17a6*) in Kiss1 neurons and found that glutamate release was completely abrogated in the ARH population of Kiss1 neurons. Given that we have documented previously that Kiss1^AVPV/PeN^ neurons do not express Slc17a6 ([@bib61]) and do not release glutamate, we believe that the KO would be specific for Kiss1^ARH^ neurons. However, Kiss1 neurons are expressed in other brain regions, including the medial amygdala and BNST ([@bib38]), and although *Slc17a6* has not yet been documented in these neurons, we cannot rule out the possibility that vGluT2 has been deleted in extra-hypothalamic kisspeptin neurons.

Within the Kiss1^ARH^ neurocircuitry, the lack of glutamate resulted in a diminished slow EPSP in E2-treated animals. The slow EPSP is attenuated by E2 treatment ([@bib61]), and it was further reduced in E2-treated *Slc17a6* KO females. Given that the slow EPSP underlies Tac2-dependent engagement of synchronous activity in Kiss1^ARH^ neurons ([@bib61]), these findings support the idea that glutamate may play a role in Kiss1^ARH^ synchronous firing activity and LH pulsatility in the presence of high circulating levels of E2, when peptide neurotransmitters are low and glutamate levels are high in female Kiss1^ARH^ neurons. Interestingly, females with ablation of vGluT2 in Kiss1 neurons appeared to exhibit a normal ovulatory cycle, an indication that glutamatergic neurotransmission from Kiss1 neurons may not be necessary to support reproductive function. However, deletion of ERα in all kisspeptin neurons (KERKO) significantly attenuates glutamatergic synaptic input (spontaneous EPSCs) to the Kiss1^AVPV/PeN^ neurons, which could be due to lack of E2-stimulated glutamate release from Kiss1^ARH^ neurons ([@bib80]). The net result is an increase in LH pulse frequency in KERKO mice, which was proposed to represent a lack of negative feedback ([@bib80]). Clearly further experiments, including deletion of *Slc17a6* specifically in adult females, which would prevent potential developmental compensation, are necessary to determine whether glutamate and/or peptide neurotransmission from Kiss1^ARH^ neurons to Kiss1^AVPV/PeN^ neurons are involved in reproductive functions.

High-frequency stimulation of Kiss1^ARH^ neurons in slices from E2-treated OVX *Slc17a6* KO females induced a low-amplitude, inward current in POMC neurons and a low-amplitude, outward current in NPY/AgRP neurons, an indication of residual excitatory and inhibitory inputs, respectively to these neurons. Given that the high frequency stimulation has been documented to induce peptide release ([@bib61]), this is an indication that kisspeptin release from Kiss1^ARH^ neurons evoked the excitation of POMC neurons and inhibition of NPY/AgRP neurons. In agreement with previous studies ([@bib27]), bath application of kisspeptin activated POMC neurons most likely by signaling via the Kiss1 receptor, GPR54, which is expressed in POMC neurons. Similarly, kisspeptin inhibited firing and hyperpolarized NPY/AgRP neurons via activation of a GIRK current. The Kiss1 receptor is not expressed in NPY/AgRP neurons. However, NPFFR1 is expressed, and its agonist RFRP-3 inhibited firing and hyperpolarized NPY/AgRP neurons via activation of a GIRK current. Based on evidence that both RFRP-3 and kisspeptin bind to and activate NPFFR1 ([@bib7]), we propose that the two different neuropeptides inhibit NPY/AgRP neurons by action on the same receptor. Collectively, these data indicate that Kiss1^ARH^ neurons may use both kisspeptin and glutamate to activate POMC neurons but inhibit NPY/AgRP neurons, and compensatory kisspeptin input could be one of the reasons why deleting vGluT2 was not effective to alter body weights on a normal chow diet over the time-course of our study.

As the Kiss1 *Slc17a6* KO females did not appear to gain weight on standard low-fat mouse chow diet, we used a place preference paradigm to determine the motivation for sucrose in *Slc17a6* KO as compared to control Kiss1 and *Slc17a6* Het females ([@bib57]). These experiments revealed a preference for the sucrose-paired chamber by the E2-treated, OVX mice lacking *Slc17a6* in Kiss1 neurons compared to Kiss1^Cre^ and Het females. The *Slc17a6* Het females did not exhibit a CPP to sucrose, but did consume more sucrose in comparison to control Kiss1 females. Importantly, the E2-treated *Slc17a6* Het females expressed low levels of *Slc17a6* mRNA in Kiss1^ARH^ neurons, an indication that glutamate release was attenuated ([@bib34]), which could be why the *Slc17a6* Het females behaved more like *Slc17a6* KO than control Kiss1 animals thereby exhibiting a behavioral gene-dosage/threshold effect. While reward-seeking behaviors have not been specifically associated with Kiss1^ARH^ neurons, NPY/AgRP and POMC neurons are involved in hedonic feeding in addition to controlling homeostatic food intake ([@bib6]; [@bib33]; [@bib40]; [@bib50],[@bib51]; [@bib68]; [@bib76]) Although it is clear that homeostatic feeding is regulated by NPY/AgRP and POMC neurons, the motivational drive to eat palatable foods are more complex behaviors that are regulated by multiple interconnected neural systems ([@bib11]; [@bib19]; [@bib24]; [@bib67]). Therefore, further analyses of the neural circuits underlying these physiological responses are essential for understanding such complex behavior. Regardless, our findings have revealed a novel role for glutamate neurotransmission by Kiss1^ARH^ neurons ([Figure 17](#fig17){ref-type="fig"}), which appears to be sex-specific based on our findings that glutamate signaling is regulated differently in female and male ([@bib46]) mice.

Materials and methods {#s4}
=====================

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Reagent type\          Designation           Source or reference         Identifiers                                                              Additional\
  (species)or resource                                                                                                                              information
  ---------------------- --------------------- --------------------------- ------------------------------------------------------------------------ ------------------------------------------
  Strain, strain\        C57BL/6J              The Jackson\                RRID\                                                                    
  background\                                  laboratory                  :[IMSR_JAX:000664](https://scicrunch.org/resolver/IMSR_JAX:000664)       
  (*M.Musculus*)                                                                                                                                    

  Genetic\               *Kiss1^Cre:GFP^*      Dr. Robert A Steiner;\      RRID:[IMSR_JAX:017701](https://scicrunch.org/resolver/IMSR_JAX:017701)   Full\
  reagent\                                     University of\                                                                                       nomenclature: Kiss1^tm1.1(cre/EGFP)Stei^
  (*M.Musculus*)                               Washington;\                                                                                         
                                               PMID:21933870                                                                                        

  Genetic\               Kiss1^Cre:GFP^\       Dr. Richard D.\                                                                                      
  reagent\               version 2 (V2)        Palmiter;\                                                                                           
  (*M.Musculus*)                               University of\                                                                                       
                                               Washington;\                                                                                         
                                               PMID: 29336844                                                                                       

  Genetic\               *Pomc^EGFP^*          Dr. Malcolm J.\             RRID:[IMSR_JAX:009593](https://scicrunch.org/resolver/IMSR_JAX:009593)   Full nomenclature:\
  reagent\                                     Low; University\                                                                                     Tg(Pomc-EGFP)\
  (*M.Musculus*)                               of Michigan;\                                                                                        1Low
                                               PMID:11373681                                                                                        

  Genetic\               *Npy^GFP^*            Dr. Brad\                   JAX stock \#006417                                                       Full nomenclature:\
  reagent\                                     Lowell; Harvard\                                                                                     Tg(Npy-hrGFP)\
  (*M.Musculus*)                               University; PMID:19357287                                                                            1Lowl

  Genetic\               AAV1-Ef1α-DIO-\       Dr. Stephanie L.\                                                                                    
  reagent (*Adeno-*\     ChR2:YFP              Padilla; University\                                                                                 
  *associated virus*)                          of Washington;\                                                                                      
                                               PMID: 25429312                                                                                       

  Genetic\               AAV1-Ef1α-DIO-\       Dr. Stephanie L.\                                                                                    
  reagent (*Adeno-*\     ChR2: mCherry         Padilla; University\                                                                                 
  *associated virus*)                          of Washington;\                                                                                      
                                               PMID: 25429312                                                                                       

  Antibody               Anti-mCherry\         Abcam                       Abcam: ab167453\                                                         (1:10,000)
                         (rabbit polyclonal)                               RRID:[AB_2571870](https://scicrunch.org/resolver/AB_2571870)             

  Antibody               Anti-kisspeptin\      Dr. Alain Caraty\           No. 564\                                                                 (1:2500)
                         (rabbit polyclonal)   Universite Francois\        AB_2622231                                                               
                                               -Rabelais Tours;\                                                                                    
                                               PMID:16621281                                                                                        

  Antibody               Goat anti-rabbit\     Life Technologies\          Cat. No.: \# A-11037\                                                    (1:500)
                         conjugated to\        (ThermoFisher)              RRID: [AB_2534095](https://scicrunch.org/resolver/AB_2534095)            
                         Alexa 594                                                                                                                  

  Antibody               Goat anti-rabbit\     Life Technologies\          Cat. No.: \# A-11034\                                                    (1:500)
                         conjugated to\        (ThermoFisher)              RRID: [AB_2576217](https://scicrunch.org/resolver/AB_2576217)            
                         Alexa 488                                                                                                                  
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Mice {#s4-1}
----

 All procedures conducted with animals were according to the National Institutes of Health Guide for the Care and Use of Laboratory Animals with approval for all of the animal use procedures from the Oregon Health and Science University (OHSU) and/or the University of Washington (UW) Animal Care and Use Committees.

*Kiss1^Cre:GFP^* ([@bib31]), Kiss1^Cre:GFP^ version 2 (V2) ([@bib49]), *Pomc^EGFP^* ([@bib15]), *Npy^GFP^* ([@bib78]), *Kiss1^Cre:GFP^::Pomc^EGFP^* and *Kiss1^Cre:GFP^::Npy^GFP^* female mice were housed under constant temperature (21--23°C) and 12 hr light, 12 hr dark cycle schedule (lights on at 0600 and lights off at 1800 hr), with free access to food (Lab Diets 5L0D) and water. Where specified, *Kiss1^Cre:GFP^, Kiss1^Cre:GFP^::Pomc^EGFP^* and *Kiss1^Cre:GFP^::Npy^GFP^* mice received viral injections to express channelrhodopsin 2 (ChR2) in Kiss1^ARH^ neurons (see below). *Kiss1^Cre:GFP^::Pomc^EGFP^* and *Kiss1^Cre:GFP^::Npy^GFP^* mice were produced by crossing heterozygous *Kiss1^Cre:GFP^* mice with *Pomc^EGFP^* and *Npy^GFP^* mice, respectively.

Kiss1^Cre:GFP^ version 1 (V1) and Kiss1^Cre:GFP^ V2 {#s4-2}
---------------------------------------------------

The offspring from Kiss1^Cre;GFP^ V1 animals crossed with a reporter line like lacZ, sometimes showed ectopic expression ([@bib31]). Subsequently, the Palmiter group produced Kiss1^Cre:GFP^ V2 animals in which the Cre was less efficient ([@bib49]), thereby significantly decreasing the likelihood of ectopic expression ([@bib75]). However, Kiss1^Cre:GFP^ V2 animals express less GFP and, therefore, the individual Kiss1 neurons are more difficult to see in a slice preparation unless injected with Cre-dependent ChR2-mCherry (or ChR2-YFP) to label Kiss1 neurons. Currently, we have used both Kiss1^Cre:GFP^ lines and we have found no differences between the two in terms of the molecular, electrophysiological and optogenetic characterization.

AAV delivery {#s4-3}
------------

 Viruses were prepared at the University of Washington according to published methods ([@bib30]). Fourteen to twenty-one days prior to each experiment, *Kiss1^Cre:GFP^*, Kiss1^Cre:GFP, ^V2, *Kiss1^Cre:GFP^::Pomc^EGFP^ or Kiss1^Cre:GFP^::Npy^GFP^* female mice (\>60 days old) received bilateral ARH injections of a Cre-dependent adeno-associated viral (AAV; serotype 1) vector encoding ChR2 fused to yellow fluorescent protein, YFP (AAV-EF1α-ChR2:YFP) or mCherry (AAV-EF1α-ChR2:mCh) as described ([@bib46]). Briefly, using aseptic techniques, anesthetized mice (1.5% isoflurane/O~2~) were placed in a Kopf stereotaxic apparatus (Tujunga, CA) and received a medial skin incision to expose the surface of the skull. Two holes were drilled into the skull at designated coordinates from bregma (x: ± 0.30 mm; y: -1.200 mm). For the viral injections, a glass micropipette (Drummond Scientific \#3-000-203-G/X; Broomall, PA) was fabricated with a Narishige PE-2 puller and beveled (tip diameter = 45 µm), filled with mineral oil and loaded with an aliquot of AAV using a Nanoject II (Drummond Scientific). The pipette tip was positioned at x: -0.30 mm; y: -1.200 mm and lowered to z: -5.800 mm (surface of brain z = 0.0 mm). The AAV (2.0 × 10^12^ particles/ml) was injected at a rate of 100 nl/min (300 nl total), raised to −5.700 mm for a second injection (200 nl total) and then left in place for 10 min post-injection before the pipette was slowly removed from the brain. The other hemisphere injection was done at the same y and z coordinates, but at x: +0.30 mm. The skin incision was closed using skin adhesive, and each mouse received analgesia (Carprofen; 5 mg/kg; subcutaneous) for two days post-operation. These arcuate injections only labeled Kiss1 cell bodies in the ARH as evaluated using immunocytochemistry and scRT-PCR (see [Figure 6](#fig6){ref-type="fig"}) ([@bib46]) ([@bib61]).

Ovariectomy (OVX) and estradiol treatment {#s4-4}
-----------------------------------------

We were interested in exploring the actions of preovulatory levels of 17β-Estradiol (E2) on neurotransmitter expression, neuronal activity and behavior in females. Therefore, we used an E2-treatment regimen that we have documented induces a preovulatory surge of luteinizing hormone (LH) in GnRH^GFP^ and Kiss1^GFP^ females ([@bib8]; [@bib85]). When necessary, at least seven days prior to each experiment, ovaries were removed as described previously while under isoflurane inhalation anesthesia (Piramal Enterprises Limited, Andhra Pradesh, India) ([@bib85]). Each mouse received analgesia (Carprofen; 5 mg/kg; subcutaneous) on the day of operation. 17β-Estradiol benzoate (E2) treatments were as described previously ([@bib85]). Briefly, each animal was injected on day 5 following OVX with 0.25 μg E2, followed on day 6 with 1.50 μg E2 and used for experiments on day 7. High circulating (proestrous) levels of 17β-estradiol (E2) were verified by the uterine weights (\>100 mg) at the time of the hypothalamic slice preparation.

qPCR and scRT-PCR {#s4-5}
-----------------

qPCR and scRT-PCR were conducted as previously described ([@bib8]). Briefly, the ARH was microdissected from 240 μm basal hypothalamic coronal slices (3--4 slices/per mouse) from OVX oil- and estradiol-treated female *Kiss1^Cre:GFP^* mice (n = 5--7 animals/group; qPCR), POMC^EGFP^, and NPY/AgRP^GFP^ mice (n = 5 animals each/group; qPCR). The dispersed cells were visualized using a Leitz inverted fluorescent microscope, patched, and then harvested with gentle suction to the pipette using a Xenoworks digital micromanipulator system (Sutter Instrument; Novato, CA) and expelled into a siliconized 0.65 ml microcentrifuge tube containing a solution of 1X Invitrogen Superscript III Buffer, 15 U of RNasin (Promega), 10 mM dithiothreitol and diethylpyrocarbonate-treated water in a total of 5 μl for a single cell (1 cell/tube for scRT-PCR) or 8 μl for pooled cells (5 cells/tube for qPCR). cDNA synthesis was performed on single cells and pools of 5 cells as previously described ([@bib8]) and stored at −20°C. Controls included non-fluorescent cells, artificial CSF (aCSF), single cells without reverse transcriptase (RT) and tissue controls with and without RT. Primers for the genes that encode for Kiss1 (*Kiss1*), NKB (*Tac2*), NKB receptor (*Tacr3*) Dynorphin (*Pdyn*), POMC (*Pomc*), NPY (*Npy*), AgRP (*Agrp*), vGluT2 (*Slc17a6*), vGAT (*Slc32a1*), mGlur1 (*Grm1*), mGlur2 (*Grm2*) mGlur3 (*Grm3*), mGlur5 (*Grm5*), mGlur7 (*Grm7*), GAPDH (*Gapdh*), β-actin (*Actb*), Ca~V~3.1 (*Cacna1g*), HCN1 (*Hcn1*) and HCN2 (*Hcn2*) were designed using Clone Manager software (Sci Ed Software) to cross at least one intron-exon boundary and optimized as previously described ([@bib8]; [@bib46]). See [Table 1](#table1){ref-type="table"} for primer sequences and optimal annealing temperature for all genes, as well as amplification efficiency for each gene used for quantitative analysis. Note that for qPCR, the annealing temperature for all genes was set at 60°C. Primers for qPCR were further tested for efficiency (*E* = 10^(−1/*m*)^ -- 1; [Table 1](#table1){ref-type="table"}) ([@bib42]; [@bib54]). qPCR was performed on a Quantstudio 7 Flex Real-Time PCR System (Life Technologies) using the Power Sybrgreen (Life Technologies) mastermix method according to established protocols ([@bib8]). The comparative ∆∆CT method ([@bib42]; [@bib54]) was used to determine values from duplicate or triplicate samples of 4 µl for the target genes and 2 µl for the reference gene. The relative linear quantity was determined using the 2^-∆∆CT^ equation ([@bib8]). In order to determine the relative expression levels of target genes in Kiss1^ARH^ neurons obtained from OVX and estradiol-treated animals, the mean ∆CT for the target genes from the OVX female samples were used as the calibrator, and the data were expressed as *n*-fold change in gene expression normalized to the reference gene *Gapdh* (Kiss1 neurons) or *Actb* (NPY neurons) relative to the calibrator. For quantification differences between the mRNA expression of *Tac2* (NKB), *Pdyn*, *Kiss1* and *Slc17a6* in Kiss1^ARH^ neurons, the mean ∆ CT for the target gene *Tacr3* from the OVX female samples were used as the calibrator. For quantification of *Grm7* in NPY/AgRP neurons, the mean ∆CT for the target genes from the OVX female samples were used as the calibrator as described above. scRT-PCR was performed on 3 µl of cDNA in a 30 µl reaction volume and amplified 50 cycles using a C1000 Thermal Cycler (Bio-Rad).The PCR product was visualized with ethidium bromide on a 2% agarose gel.

Electrophysiology and optogenetics  {#s4-6}
-----------------------------------

Coronal brain slices containing the ARH from AAV1-EF1α-DIO-ChR2:YFP injected *Kiss1^Cre:GFP^* female mice, *Pomc^EGFP^* female mice, *Npy^GFP^* female mice, AAV1-EF1α-DIO-ChR2:mCh injected *Kiss1^Cre:GFP^::Pomc^EGFP^* female mice and AAV1-EF1α-DIO-ChR2:mCh injected *Kiss1^Cre:GFP^::Npy^GFP^* female mice were prepared as previously described ([@bib46]; [@bib58]). Whole-cell patch recordings were performed in voltage-clamp and current-clamp using an Olympus BX51W1 upright microscope equipped with video-enhanced, infrared-differential interference contrast (IR-DIC) and an Exfo X-Cite 120 Series fluorescence light source. Electrodes were fabricated from borosilicate glass (1.5 mm outer diameter; World Precision Instruments, Sarasota, FL) and filled with a normal internal solution (in mm): 128 potassium gluconate, 10 NaCl, 1 MgCl~2~, 11 EGTA, 10 HEPES, 2 ATP, and 0.25 GTP (pH was adjusted to 7.3--7.4 with 1N KOH, 290--300 mOsm). Pipette resistances ranged from 3 to 5 MΩ. In whole cell configuration, access resistance was less than 20 MΩ; access resistance was 80% compensated. To display reversal potential and rectification characteristics of the ligand-activated currents, I--V plots were constructed by voltage ramps from −100 mV to 0 mV applied over 2 s from a holding potential of -- 60 mV. For some experiments measuring the ramp current-voltage (I-V), K^+^-gluconate in the normal internal solution was replaced with Cs^+^-gluconate (pH 7.35 with CsOH) ([@bib60]), and the extracellular solution contained Na^+^, K^+^, I~h~ (HCN), Ca^2+^, and GABA~A~ channel blockers (in mM: NaCl, 126; 4-aminopyridine, 5; KCl, 2.5; MgCl~2~, 1.2; CsCl, 2; CaCl~2~, 1.4; CoCl~2~, 1; nifedipine, 0.01; HEPES, 20; NaOH, 8; glucose, 10; tetrodotoxin (TTX), 0.001; picrotoxin, 0.1). For optogenetic stimulation, a light-induced response was evoked using a light-emitting diode (LED) 470 nm blue light source controlled by a variable 2A driver (ThorLabs, Newton, NJ) at 0.5--20 Hz with the light path directly delivered through an Olympus 40 × water immersion lens. For high-frequency (20 Hz) stimulation the length of stimulation was 10 s ([@bib61]). Electrophysiological signals were digitized with Digidata 1322A (Molecular Devices, Foster City, CA), and the data were analyzed using p-Clamp software (version 9.2, Molecular Devices). The liquid junction potential was corrected for all data analyses. After recording, the cytosol of non-fluorescent recorded cells was harvested and used for *post-hoc* identification by scRT-PCR using the same protocol as for the dispersed single cells (see above).

Deletion of Slc17a6 in Kiss1^Cre:GFP^ neurons  {#s4-7}
----------------------------------------------

The deletion of *Slc17a6* specifically in Kiss1 neurons was accomplished according to previously described procedures ([@bib35]) by breeding *Slc17a6^lox/lox^* mice with *Slc17a6^+/Δ^::Kiss1^Cre:GFP/+^* mice. *Slc17a6^Δ/lox^::Kiss1^Cre:GFP/+^* (KO) and *Slc17a6^+/lox^::Kiss1^Cre:GFP/+^* (Het mice) were determined using the following primers: CGC AGC CAT TCA CCT GTC TAA G; AAA GGT CCT GGA TCA GAG CAG G; and CAG TGT GCT GTA ACT GAG ATA GT ([@bib75]). Approximately 25% of the offspring from this cross were conditional knockout *Slc17a6^Δ/lox^::Kiss1^Cre:GFP/+^* and \~ 25% were heterozygous (Het) *Slc17a6^+/lox^::Kiss1^Cre:GFP/+^*. The Cre-negative mice would be Slc17a6^+/lox^ (WT) or *Slc17a6^∆/+^* (Het). PCR of tail DNA that detected both the lox and the Δ (null) alleles of *Slc17a6* was used to detect unexpected (ectopic) recombination that sometimes occurs with this cross ([@bib75]). Mice with ectopic recombination were not used for experiments.

Estrous cycle and fertility  {#s4-8}
----------------------------

Prior to monitoring the estrous cycle, females were habituated to handling for at least 3 days, and during the study, each cage was *only* handled by the investigator. To track the estrous cycle, a vaginal lavage with sterile 0.1M PBS was performed daily between 0700 hr to 0800 hr, and evaluated by light microscopy for the appearance of: cornified epithelial cells, leukocytes, and nucleated epithelial cells. The loss of leukocytes and presence of an abundance of nucleated cells was scored as proestrus, while the transition to primarily cornified epithelial cells was scored as estrus. Note one acyclic mouse was excluded from both the wild type and homozygous groups. For fertility measurements, females were mated with a sexually-experienced wild type male on day 0. Litters were tracked from day 16 through 30. The length of time until conception was calculated as the number of days until parturition minus a 20 day gestation period. Note, two wild type and two homozygous animals were excluded because they did not give birth within the 30 day trial.

Conditioned place preference (CPP) behavioral assay for vGluT2 deleted and control Kiss1 animals {#s4-9}
------------------------------------------------------------------------------------------------

*Slc17a6* Het (*Slc17a6^+/lox^::Kiss1^Cre:GFP/+^*, n = 4) and KO (*Slc17a6^Δ/lox^::Kiss1^Cre:GFP/+^*, n = 8) females were initially injected with AAV1-DIO-ChR2:YFP in the arcuate nucleus as described above in order to do optogenetic experiments in vitro following in vivo conditioned place preference (CPP) tests. Control Kiss1 (Kiss1^Cre:GFP/+^) females (n = 8), destined for CPP analysis, received sham surgery, but without viral injection. In addition, we prepared another set of control females (*Kiss^Cre:GFP/+^*, n = 7), which similar to *Slc17a6* Het and KO females received viral injection prior to the CPP test. Both Kiss1 control groups exhibited similar results in the CPP test, indicating that the presence of unstimulated ChR2::YFP fusion protein had no effect on behavior.

The animals were OVX at the time of viral injections or sham surgery and received equal cyclical (\~every 3--5 days) priming 0.25 μg and/or a surge 1.0--1.5 μg dose of 17β-estradiol benzoate (E2) ([@bib8]) prior to and throughout the CPP procedure (see [Figure 15](#fig15){ref-type="fig"}). The E2-treatment started on days 5--6 following OVX with a 2 μg dose, followed 6--7 days later with another 2 μg dose during the recovery period from viral or sham injections. Thereafter, the cyclical E2-treatment was initiated with a 0.25 μg dose followed the day after with 1.5 μg E2, a treatment shown to induce a LH surge in GnRH mice ([@bib8]) and Kiss1 mice ([@bib85]). As indicated in [Figure 15](#fig15){ref-type="fig"}, we used this E2-treatment immediately prior to the baseline place preference (BPP; initiated 18--20 days after OVX) and prior to the CPP in all groups. The animals were handled daily over a 7 day period prior to the CPP procedure in order to adapt to the investigator and minimize handling stress. The protocol for inducing CPP with sucrose consisted of four phases over the course of 11 days (sucrose habituation, a BPP test, sucrose conditioning, and a CPP test) as depicted in [Figure 15](#fig15){ref-type="fig"}. During sucrose habituation (Day −1), mice received sucrose in their home cage to prevent neophobia. Animals received 0.5 g of sucrose reward pellets (TestDiet, Richmond, IN) in a scintillation vial lid left in cages overnight. The next morning cages were changed so no sucrose remained. All behavior testing was conducted in a separate room kept on the same light schedule as the colony room. Mice were transferred into the animal testing room 1 hr prior to dark onset (1700 hr). The CPP behavioral assay was conducted in the dark cycle (beginning at 1800 hr). During the baseline place preference test (Day 1), mice were placed in the central chamber of a three-chamber place preference apparatus (Product Number: MED-CPP-3013, Med Associates Inc, Fairfax, VT) to determine pretest values. Doors were left open for mice to explore all three chambers for 15 min. An unbiased assignment was used where mice for each experimental group Kiss1^Cre:GFP^ controls, vGluT2 KO (*Slc17a6^Δ/lox^::Kiss1^Cre:GFP/+^*), and heterozygous vGluT2 animals (Slc17a6^+/lox^::*Kiss1^Cre:GFP/+^*) were subdivided into counterbalanced subgroups based on their assigned conditioning chamber (white or black chamber) ([@bib17], [@bib18]). During the sucrose conditioning phase, mice received sucrose-filled lids (CS+, Days 2, 4, 6, 8) in one chamber or empty lids (CS-, Days 3, 5, 7, 9) in the other chamber on alternating days ([Figure 15](#fig15){ref-type="fig"}). Mice were confined to a chamber (black or white) with access to sucrose (0.5 g) or without it for 30 min. Lids were stabilized in the chamber with heavy-duty magnets. We had separate sets of lids and magnets for paired (sucrose access) and unpaired days (no sucrose access). To test for acquisition of a CPP for sucrose (Day 10), mice were placed in the central chamber of the apparatus with door open for 15 min. Time spent in the sucrose-paired chamber was recorded pretest (Day 1) and posttest (Day 10). After each animal, the chambers were wiped down with 70% ethanol and paper towels located at the bottom of cages were replaced. At the end of the testing period, animals were returned to the colony room. All animals had free access to normal chow in their home cage.

Drugs {#s4-10}
-----

 All drugs were purchased from Tocris Bioscience (Minneapolis, MN) unless otherwise specified, and made up as stock solutions as follows: DL-amino-5-phosphonovaleric acid (AP5) (50 mM), 6-cyano-7-nitroquinoxaline-2,3-dione (CNQX) (10 mM), 4-Aminopyridine (4-AP) (100 mM), 3,5-dihydroxyphenylglycine (DHPG) (50 mM), (2*S*,2\'*R*,3\'*R*)−2-(2\',3\'-Dicarboxycyclopropyl)glycine (DCG-IV) (10 mM), and RFRP 3 (human, 10 mM) were dissolved in H~2~O. Tetrodotoxin (TTX) was purchased from Alomone Labs (Jerusalem, Israel) (1 mM) and was dissolved in H~2~O. Bicuculline methiodide (20 mM) was purchased from Sigma-Aldrich (St Louis, MO) and was dissolved in dimethylsulfoxide (DMSO). Picrotoxin (100 mM) was dissolved in DMSO. Kisspeptin-10 \[Mouse Kiss1 (110--119)-NH2; Kp-10, from Phoenix Pharmaceuticals (Belmont, CA)\] (100 μM) was dissolved in H~2~O. The mGluR7 agonist AMN082 dihydrochloride (10 mM) was purchased from Abcam (Cambridge, MA) and was dissolved in DMSO. The mGluR7 antagonist ADX71743 (10 mM) was dissolved in DMSO. Baclofen was purchased from Sigma-Aldrich (St Louis, MO) and dissolved in 0.1 N HCl to a stock concentration of 40 mM. Aliquots of the stock solutions were stored at −20°C until needed.

Immunocytochemistry  {#s4-11}
--------------------

Female Kiss1^CreGFP^ V2 mice, with injection of ChR2-mCherry in the ARH, were prepared for immunocytochemistry as described previously ([@bib66]). Briefly, coronal hypothalamic blocks (2 mm each) were fixed by immersion in 4% paraformaldehyde, cryoprotected in 20% sucrose solution, frozen at −55°C, sectioned coronally on a cryostat at 20 μm, and thaw-mounted on Superfrost Plus slides (Thermo Fisher Scientific). Some sections were rinsed in PB (0.1M phosphate buffer, pH 7.4; all rinses were in PB for at least 30 min), and then incubated for 48 hr at 4° C in rabbit polyclonal antiserum against mCherry (1:10,000; ab167453 Abcam Inc, Cambridge MA). Some preoptic sections were reacted with rabbit polyclonal antiserum against kisspeptin as described previously ([@bib9]) using the Caraty kisspeptin 10 antibody (no. 564; 1:2500) ([@bib26]). After rinsing, sections stained for mCherry were incubated in goat-antirabbit IgG antibody conjugated to Alexa 594 (1:500; Jackson Immunoresearch). Sections stained for kisspeptin, were incubated in goat-antirabbit IgG antibody conjugated to Alexa 488 (1:500; Jackson Immunoresearch). Following a final rinse, slides were coverslipped with gelvatol containing the anti-fading agent 1,4-diazabicyclo(2,2)octane (Sigma-Aldrich, St Louis, MO).

Imaging  {#s4-12}
--------

Photomicrographs of ARH YFP or mCherry expression were acquired using an Olympus BX51W1 upright microscope equipped with a Rolera XR Fast 1394 camera and a Nikon E800 fluorescent microscope equipped with DS-U2 camera. Confocal photomicrographs were acquired using a Zeiss LSM 510 and a Zeiss LSM 780 confocal microscopes, each equipped with 20x and 40x (NA 0.8) APO objectives with Zen software.

Data Analysis {#s4-13}
-------------

For qPCR three to seven Kiss1 or NPY/AgRP neuronal pools (5 cells/pool) from each animal were run in duplicate or triplicate for mRNAs that encode for Kiss1, Tac2, Pdyn, Tacr3, vGluT2, vGAT, Ca~V~3.1, HCN1, HCN2, mGluR7 *and* GAPDH or β-actin and the mean value of each gene from each animal was used for statistical analysis. Data are expressed as Mean ± SEM and were analyzed using a one-way ANOVA and Tukey's multiple comparison *post-hoc* test, or an unpaired student's t-test. Since mRNA for vGAT was below the level of detectability (CT 36) in ARH Kiss1 neurons, we report it as not detectable. For scRT-PCR the number of Kiss1^GFP^, POMC^EGFP^ and NPY/AgRP^GFP^ neurons expressing each transcript was counted for each animal and the mean number of neurons/animal was determined and used for further analysis of Mean, SEM, and percentage expression. Electrophysiology data are expressed as Mean ± SEM and were analyzed using either an unpaired Student's t-test (paired-pulse experiment) or a one-way ANOVA and Newman-Keuls multiple comparison *post-hoc* test (POMC and AgRP pharmacology experiments).

10.7554/eLife.35656.032

###### Primer Table

  ----------------------------------------------------------------------------------------------------------------------------------
  Gene name\               Accession\     Primer\         Product\      Annealing\     Efficiency\   Efficiency r^2^   Efficiency\
  (encodes for)            Number         Location (nt)   Length (bp)   Temp (°C)      Slope                           %
  ------------------------ -------------- --------------- ------------- -------------- ------------- ----------------- -------------
  *Kiss1* (Kiss1)^a,b^     NM_178260      64--80\         120           57^a^, 60^b^   −3.410        0.989             97
                                          167--183                                                                     

  *Pomc* (POMC)^a^         NM_008895      145--164\       200           60.5                                           
                                          327--344                                                                     

  *Npy* (NPY)^a^           NM_023456      106--125\       182           60                                             
                                          268--287                                                                     

  *Grm1* (mGluR1)^a^       NM_001114333   2044--2063\     186           59                                             
                                          2210--2229                                                                   

  *Grm2* (mGluR2)^a^       NM_001160353   2448--2466\     145           59                                             
                                          2574--2592                                                                   

  *Grm5* (mGluR5)^a^       NM_01143834    1436--1453\     247           59                                             
                                          1663--1682                                                                   

  *Grm7* (mGluR7)^a,b^     NM_001346640   1354--1373\     109           55^a^, 60^b^   −3.306        0.985             100
                                          1445--1462                                                                   

  *Npffr1* (Npffr1)^a^     NM_001177511   360--378\       111           55                                             
                                          450--470                                                                     

  *Kiss1r* (GPR54)^a^      NM_053244      1900--1917\     245           60                                             
                                          2125--2144                                                                   

  *Slc17a6* (vGluT2)^c^    NM_080853      1038--1056\     194           57                                             
                                          1213--1231                                                                   

  *Slc17a6* (vGluT2)^b^    NM_080853      872--889\       113           60             −3.293        0.920             100
                                          967--984                                                                     

  *Slc32a1* (vGAT)^b^      NM_009508      813--834\       137           60             −3.290        0.906             100
                                          928--949                                                                     

  *Pdyn* (Dyn)^b^          NM_018863      210--228\       154           60             −3.516        0.990             93
                                          345--363                                                                     

  *Tac2* (NKB)^a,b^        NM_009312      79--97\         147           60             −3.324        0.992             100
                                          207--225                                                                     

  *Tacr3* (Tacr3)^b^       NM_021382      764--783\       120           60             −3.504        0.911             93
                                          864--883                                                                     

  *Cacna1g* (Cav 3.1)^b^   NM_009783      5004--5025\     80            60             −3.372        0.968             98
                                          5060--5083                                                                   

  *Hcn1* (HCN1)^b^         NM_010408      1527--1546\     136           60             −3.253        0.958             100
                                          1641--1662                                                                   

  *Hcn2* (HCN2)^b^         NM_008226      1122--1143\     97            60             −3.279        0.969             100
                                          1199--1218                                                                   

  *Gapdh* (GAPDH)^b^       NM_008084      689--706\       93            60             −3.352        0.998             99
                                          764--781                                                                     

  *Actb* (β-actin)^b^      NM_007393      446--465\       110           60             −3.465        0.996             95
                                          535--555                                                                     
  ----------------------------------------------------------------------------------------------------------------------------------

^a^primers used for scRT-PCR.

^b^primers used for qPCR.

^c^primers used to confirm the vGluT2-KO using scRT-PCR.

Behavioral data are depicted as Mean ± SEM. CPP and sucrose consumption were analyzed using a two-way ANOVA (experimental group as the between-subject factor and CPP protocol days, pretest and posttest, as the within-subject factor) followed by Bonferroni multiple comparison *post-hoc* test. Body weight gain over the 10 day CPP period was analyzed using a one-way ANOVA followed by Tukey's multiple comparison *post-hoc* test.
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Harvard University

United States

In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.

Thank you for submitting your article \"Glutamate output from arcuate nucleus Kisspeptin neurons regulates motivational drive for palatable food in females\" for consideration by *eLife*. Your article has been reviewed by a Senior Editor, a Reviewing Editor, and three reviewers.. The reviewers have opted to remain anonymous.

The reviewers have discussed the reviews with one another and the Reviewing Editor has drafted this decision to help you prepare a revised submission.

The reviewers agree that your manuscript successfully uses state of the art in vitro methods to extend findings from in vivo experiments to examine the functional relationships between the estrogen-sensitive kisspeptin neurons of the arcuate nucleus and hypothalamic circuits. However, there are several issues that need to be addressed according to the three reviewers:

Essential revisions

1\) The major concern is that the conditioned place preference (CPP) conclusions are not supported by the results and should not be overstated in the title. Specifically, the fact that WT OVX-E2 mice do not develop CPP for sucrose raises the issue of whether this test can adequately assess food preference/reward in this model system. Although the authors acknowledge the challenges to measure CPP for sucrose in mice, it is premature to conclude that KO mice have a behavioral phenotype compared to controls not showing the expected response. Alternative CPP protocols (food restriction, high fat-high sucrose pellets) should be considered as well as operant conditioning to measure food reward. Also, simple tests such as a fast-refeeding challenge, food preference or high-fat feeding may help highlight a feeding or metabolic phenotype. Based on the data showing normal energy balance in KO mice, the authors cannot conclude: \"Collectively, these data indicate that Kiss1^ARH^ neurons may use both kisspeptin and glutamate to activate POMC but inhibit NPY neurons and thus, participate to maintain normal energy balance\".

Accordingly, we suggest that you drop the behavioral work (conditional place preference (CCP) paradigm) and concentrate on addressing the neurobiological issues of specificity of expression etc. leaving behavioral work to a later paper.

2\) The physiological relevance of the work is limited because the experiments were done in ovariectomized (OVX) mice in the absence or presence of estradiol (E2) supplementation. Unless the generalization of the work was in the context of abrupt onset of menopause or ovariectomy in patients, it does not seem widely applicable. The study would have had much more breadth if it had been conducted in female mice at key stages of the estrous cycle such as diestrus and proestrus. Typically, studies that intend to use the OVX and the OVX + E2 mouse model to recapitulate the changes in circulating E2 levels occurring during the actual estrous cycle usually implant a silastic capsule filled with E2 in OVX mice to avoid full deprivation in E2 (a condition that never happens in mice) and mimic the diestrus stage.

3\) The authors have to be cautious when they state that because *Slc17a6* is not expressed in the kisspeptin neurons of the preoptic region (AVPV/PeN), the lox/Cre mediated ablation of *Slc17a6* using the kisspeptin promoter is specific for kisspeptin neuron in the arcuate nucleus (ARH). there is increasing evidence that the kisspeptin gene is expressed in extra-hyphothalamic areas, some of which could well be involved in controlling motivated behavior. The only way the authors could convincingly show that ARH kisspeptin neurons indeed regulate motivational drive for palatable food, as claimed in the title of the paper, would be to perform experiments in mice in which they selectively manipulate opto/chemo-genetically ARH kisspeptin neurons in mice in vivo (using the tools the authors master well) and hopefully validate their interesting findings in the animal model in which they knockout selectively *Slc17a6* KO only in kisspeptin neurons. In addition, being able to manipulate (stimulate) the activity of ARH kisspeptin neurons in vivo, this would also extend the significance of the present study by determining whether the kisspeptin neurons could actually be the glutamatergic neurons of the ARH that have recently been described to mediate satiety in mice fed at libitum (see Resch et al., 2017, which has not been discussed in the paper).

4\) Finally, the authors conclude (Abstract) that the E2-driven increase in excitability and glutamate release from ARH kisspeptin neurons plays a significant role in dampening the motivational drive for palatable food during critical reproductive states. Unfortunately, the authors only performed the experiments in OVX + E2 animals. Because the authors have studied the effect of *Slc17a6* KO in kisspeptin neurons on the estrous cycle and showed that it had no effect on it, they should study condition place preference in these animals in diestrus and proestrus to convincingly corroborate their statement.

Specific comments

1\) Results section: The methods for these experiments are not very clear. How did they measure ion channel currents? What channel blockers did the authors use and in what concentration? Stock concentrations are given in the methods but not the final working concentration. For rebound firing -- what is the current injection protocol, how long after the hyperpolarizing current do the authors consider a spike to be a rebound spike?

2\) Results section: It would be good to see some discussion about why there is a difference in the response of NPY neurons to low frequency vs high frequency stimulation of Kiss1^ARH^ neurons. The authors suggest that the high frequency stimulation is more physiological, in which case I don\'t understand the point of doing the low frequency stimulation. Do low frequency stimulations not activate the inhibitory metabotropic glutamate receptors? Would there be any physiological conditions where the release of glutamate from Kiss1^ARH^ neurons switches from being inhibitory for NPY to being excitatory?

3\) A description of the validation of the injection sites of AVV is not clearly stated.

4\) AVPV Kiss1 neurons has been described to project to the ARC (Yeo SH et al., 2016). Because the mouse model expresses Cre in both neuronal populations, even proper injection of AAVs into the ARC could infect AVPV Kiss1 neurons. Therefore, while the lack of action in the presence of TTX indicates that there is synaptic activation, this does not exclude that other AVPV Kiss1 neurons may contact and activate each other when photo-stimulated. Evidence that cell bodies of AVPV Kiss1 neurons (that should be GFP labeled) are devoid of mCherry is necessary.

5\) Indicate at what time after OVX or E2 replacement the experiments were performed as well as dose of E2 used.

6\) Subsection "High frequency stimulation of glutamate release from Kiss1^ARH^ neurons excites POMC neurons and inhibits NPY neurons via metabotropic receptors", \"revealed a significantly reduced slow EPSP\" However, Figure 11G does not show this different to be significant.

7\) Has DHPC been used on NPY neurons and DCG-IV on POMC neurons?

8\) The authors addressed the role of mGluR2 in NPY neurons, which is expressed only in 10% of them. Therefore, the study of mGluR7, which is more abundant, is missing.

9\) E2 dramatically decreases Kiss1 expression (Figure 2) to suggest a decreased Kiss release. As such, it is expected that the Kisspeptin tone onto POMC and NPY neurons would be minimal at high Hz stimulation in OVX-E2 vs. OVX VGluT2 KO mice. Did the authors do these measurements? This should be at least discussed along with potential studies assessing the impact of E2 on responses to Kisspeptin in POMC or NPY neurons.

10\) Did the authors test the effect of high Hz stimulation of ARC Kiss1 on AVPV Kiss1 activity in VGluT2 KO mice? This aspect should be at least discussed.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

Thank you for resubmitting your work entitled \"Estrogenic-dependent Glutamatergic Neurotransmission from Kisspeptin Neurons Governs Feeding Circuits in Females\" for further consideration at *eLife*. Your revised article has been reviewed by a Senior Editor, a Reviewing Editor, and three reviewers.

The manuscript has been largely improved but there is one remaining issue that needs to be addressed before acceptance: could you please add a sentence justifying the use of the OVX and OVX+E2 animal models in the text?

10.7554/eLife.35656.036

Author response

> *The reviewers agree that your manuscript successfully uses state of the art in vitro*in vitro *methods to extend findings from in vivo*in vivo experiments to examine the functional relationships between the estrogen- sensitive kisspeptin neurons of the arcuate nucleus and hypothalamic circuits. However, there are several issues that need to be addressed according to the three reviewers:
>
> 1\) The major concern is that the conditioned place preference (CPP) conclusions are not supported by the results and should not be overstated in the title. Specifically, the fact that WT OVX-E2 mice do not develop CPP for sucrose raises the issue of whether this test can adequately assess food preference/reward in this model system. Although the authors acknowledge the challenges to measure CPP for sucrose in mice, it is premature to conclude that KO mice have a behavioral phenotype compared to controls not showing the expected response. Alternative CPP protocols (food restriction, high fat-high sucrose pellets) should be considered as well as operant conditioning to measure food reward. Also, simple tests such as a fast-refeeding challenge, food preference or high-fat feeding may help highlight a feeding or metabolic phenotype. Based on the data showing normal energy balance in KO mice, the authors cannot conclude: \"Collectively, these data indicate that Kiss1^ARH^ neurons may use both kisspeptin and glutamate to activate POMC but inhibit NPY neurons and thus, participate to maintain normal energy balance\".
>
> Accordingly, we suggest that you drop the behavioral work (conditional place preference (CCP) paradigm) and concentrate on addressing the neurobiological issues of specificity of expression etc. leaving behavioral work to a later paper.

As suggested by the reviewers, we have clarified and added new experiments concerning specificity issues raised in the critique. We have also tempered and modified our CPP conclusions (e.g., see Discussion section). We agree that it would be advantageous to test for body weight gain differences between WT and KO mice fed energy dense food. These experiments are planned with vGluT2 deletion specifically in Kiss1^ARH^ neurons in adult mice using available techniques and will be done in the future in order to more completely characterize the role of Kiss1 neurons in feeding behavior and energy balance. Still, we feel that the current CPP data adds functional significance to the cellular findings, and we would prefer to keep it; but we have deemphasized the data because more research is needed as stated above.

However, based on studies conducted in several mouse models (e.g., Kiss1^Cre^ females, n=8; POMC-EGFP females, n=10; and Kiss1^Cre^ males, n=15), E2-treated OVX female mice do not appear to develop a CPP for sucrose pellets, unless vGluT2 is deleted in Kiss1 neurons. In contrast, intact Kiss1^Cre^ males, which express lower levels of vGluT2 in Kiss1^ARH^ neurons versus E2-treated females, do develop a CPP for sucrose. Data from Kiss1^Cre^ females and males have been added as Figure 15---figure supplement 1. With the E2-treatment paradigm, which is designed to maximize *Slc17a6* mRNA expression differences in Kiss1^ARH^ neurons between the WT and Het as compared to the KO females, we would expect to find no or low preference for sucrose and no body weight gain in E2-treated WT animals. Importantly, WT, Het and KO mice were all OVX and treated equally with E2 and tested simultaneously for sucrose-reinforced CPP according to the unbiased method recommended by Dr. Chris Cunningham, who is a recognized expert on the use of CPP for measuring motivated behavior (Cunningham et al., 2006). The E2-treatment and experimental design have been described in more detail in the Materials and Methods section.

> 2\) The physiological relevance of the work is limited because the experiments were done in ovariectomized (OVX) mice in the absence or presence of estradiol (E2) supplementation. Unless the generalization of the work was in the context of abrupt onset of menopause or ovariectomy in patients, it does not seem widely applicable. The study would have had much more breadth if it had been conducted in female mice at key stages of the estrous cycle such as diestrus and proestrus. Typically, studies that intend to use the OVX and the OVX + E2 mouse model to recapitulate the changes in circulating E2 levels occurring during the actual estrous cycle usually implant a silastic capsule filled with E2 in OVX mice to avoid full deprivation in E2 (a condition that never happens in mice) and mimic the diestrus stage.

We are interested specifically in the differential estradiol regulation of neuropeptides and glutamate neurotransmission in Kiss1^ARH^ neurons as well as the corresponding behavioral effects, which is possible because of novel techniques such as single cell RT-PCR, neuropharmacology/electrophysiology and optogenetics in mouse models. Eventually, we want to explore which estrogen receptors are involved. It would be very difficult, if not impossible, to do these type of experiments in cycling female mice (see response to comment \#4). This is the reason why the majority of published behavioral data (including behavioral data in the Lowell lab, 2016, referred to below) are based on experiments done in male mice. Also, it should be noted that during proestrus in females, estrogen, progesterone and inhibin are all circulating at high levels and found to act on the hypothalamus. Therefore, the findings would not be specific for estradiol's actions.

Concerning the estradiol-treatment paradigm, we started using estradiol implants, which increased Cav3.1, Cav3.3 mRNA expression in GnRH neurons (Zhang et al., 2009). However, with E2 implants we were not able to induce a LH surge in our mouse models. Therefore, we developed an E2-injection procedure utilizing a priming dose followed by a surge-producing dose of E2, which also increases Cav3.1 and 3.3 in GnRH neurons, and with this treatment we have been able to induce a LH surge in GnRH mice (Bosch et al., 2013) and in Kiss1 mice (Zhang et al., 2013). Therefore, we believe that our model is of physiological relevance. We are aware that different steroid replacement mouse models are being used, and sometimes conflicting data are reported (see Liu et al., 2017). Unfortunately, the mouse is not a good model for studying reproduction, and eventually studies have to be done in species with long ovulatory cycle with true follicular and luteal phases such as the guinea pig and non-human primates.

*3) The authors have to be cautious when they state that because Slc17a6 is not expressed in the kisspeptin neurons of the preoptic region (AVPV/PeN), the lox/cre mediated ablation of Slc17a6 using the kisspeptin promoter is specific for kisspeptin neuron in the arcuate nucleus (ARH). there is increasing evidence that the kisspeptin gene is expressed in extra-hyphothalamic areas, some of which could well be involved in controlling motivated behavior. The only way the authors could convincingly show that ARH kisspeptin neurons indeed regulate motivational drive for palatable food, as claimed in the title of the paper, would be to perform experiments in mice in which they selectively manipulate opto/chemo-genetically ARH kisspeptin neurons in mice* in vivo *(using the tools the authors master well) and hopefully validate their interesting findings in the animal model in which they knockout selectively Slc17a6 KO only in kisspeptin neurons. In addition, being able to manipulate (stimulate) the activity of ARH kisspeptin neurons* in vivo*, this would also extend the significance of the present study by determining whether the kisspeptin neurons could actually be the glutamatergic neurons of the ARH that have recently been described to mediate satiety in mice fed at libitum (see Resch et al., 2017, which has not been discussed in the paper).*

While technically true, functionally the deletion of vGluT2 is likely to mainly affect Kiss1^ARH^ neurons. We reported in Qiu et al., 2016 that we did not detect *Slc17a6* mRNA in Kiss1^AVPV/PeN^ neurons using scRT-PCR. Also, using our scRT-PCR procedure, we detect vGAT mRNA in close to 100% of AVPV/PeN Kiss1 neurons. We have not detected glutamate release from these rostral Kiss1 neurons. High frequency stimulation releases kisspeptin (Qiu et al., 2016). Although, Kiss1 neurons have been detected in the amygdala and in the Bed Nucleus of the Stria Terminalis, these Kiss1 neurons have not been reported to express vGluT2 (See Discussion section). However, we have been more cautious and now refer to vGluT2 KO in Kiss1 neurons (rather than Kiss1^ARH^) throughout the manuscript. Also, with this in mind, we have changed the title to the following: "Estrogenic-dependent Glutamatergic Neurotransmission from Kisspeptin Neurons Governs Feeding Circuits in Females". The Fenselau et al., paper (Lowell lab), which is quite relevant for the current findings, has been added to the Discussion section.

> 4\) Finally, the authors conclude (Abstract) that the E2-driven increase in excitability and glutamate release from ARH kisspeptin neurons plays a significant role in dampening the motivational drive for palatable food during critical reproductive states. Unfortunately, the authors only performed the experiments in OVX + E2 animals. Because the authors have studied the effect of Slc17a6 KO in kisspeptin neurons on the estrous cycle and showed that it had no effect on it, they should study condition place preference in these animals in diestrus and proestrus to convincingly corroborate their statement.

Doing CPP conditioning in intact cycling female mice comparing diestrus versus proestrus animals in control and KO would be difficult and costly. In particular, it has been quite difficult to get the necessary number of *Slc17a6* KO animals of either sex. We would need to have a large group of females in order to have 8-12 diestrus and proestrus females (based on power analysis) from each group to test together for BPP and CPP (on the same day and time). Therefore, as described above, we have developed OVX vehicle- and E2-treated animals as physiological models for E2-induction of the LH surge, and for preventing weight gain in aging females (also see Asarian and Geary, 2013). However, the statement referred to in the Abstract has been modified.

> Specific comments:
>
> 1\) Results section. The methods for these experiments are not very clear. How did they measure ion channel currents? What channel blockers did the authors use and in what concentration? Stock concentrations are given in the methods but not the final working concentration. For rebound firing -- what is the current injection protocol, how long after the hyperpolarizing current do the authors consider a spike to be a rebound spike?

A citation to a previous paper was inadvertently omitted for the rebound spike measurements and is now included in the legend to Figure 2 (Zhang et al., 2013). We have added the drug concentrations for CNQX (10 μM) and AP5 (50 μM) to the legend for Figure 7, and the baclofen concentration (10 μM) for Figure 13. For Figure 14, we have included a reference (Qiu et al., 2010) in the Materials and methods section for the internal Cs^+^ concentration.

> 2\) Results section: It would be good to see some discussion about why there is a difference in the response of NPY neurons to low frequency vs high frequency stimulation of Kiss1^ARH^ neurons. The authors suggest that the high frequency stimulation is more physiological, in which case I don\'t understand the point of doing the low frequency stimulation. Do low frequency stimulations not activate the inhibitory metabotropic glutamate receptors? Would there be any physiological conditions where the release of glutamate from Kiss1^ARH^ neurons switches from being inhibitory for NPY to being excitatory?

The low frequency stimulation is used for verifying a direct synaptic connection between Kiss1^ARH^ and NPY/AgRP neurons. The high frequency stimulation probably reflects the physiological activity based on in vivo recordings (e.g., Moss et al., 1975). It is thought that mGluRs are extra-synaptic such that with the high frequency generated glutamate release there is "spillover" from the synaptic cleft to activate these receptors (Watanabe et al., 2003; Nietz et al., 2017.). This has been discussed in the Results section. The physiological conditions when Kiss1^ARH^ neuronal glutamate release would switch from being inhibitory to excitatory for NPY neurons has not yet been studied specifically. However, during high E2 conditions, such as on proestrus, animals are getting ready to mate and reproduce and at this stage of the cycle it has been shown in many animal models including primates that feeding is suppressed (see Asarian and Geary, 2006, 2013). A potential mechanism is Kiss1^ARH^ glutamatergic inhibitory output to NPY neurons. On the other hand, if animals are food deprived, it has been shown that NPY neurons receive excitatory ionotropic glutamate input (Liu et al., 2012), some of which could come from Kiss1^ARH^ neurons. This has now been added to the Discussion section.

> 3\) A description of the validation of the injection sites of AVV is not clearly stated.

In the Materials and methods section, we have described the validation of the injection site. We have published previously in males injected with AAV1-DIO-ChR2-YFP in the ARH, that 100% of the YFP neurons expressed Kiss1 mRNA (Nestor et al., 2016). In females, we have published that arcuate AAV1-DIO-ChR2-mCherry-labeled Kiss1 cells are co-expressed with Kiss1^GFP^ cells (Qiu et al., 2016). We refer to these publications in the Materials and methods section. In addition, we have done a thorough neuroanatomical analysis comparing neuronal projections following ARH and AVPV/PeN viral injections in our Kiss1 animal model. These anatomical data are being prepared for publication elsewhere. Also see response to specific comment \# 4.

> 4\) AVPV Kiss1 neurons has been described to project to the ARC (Yeo SH et al., 2016). Because the mouse model expresses Cre in both neuronal populations, even proper injection of AAVs into the ARC could infect AVPV Kiss1 neurons. Therefore, while the lack of action in the presence of TTX indicates that there is synaptic activation, this does not exclude that other AVPV Kiss1 neurons may contact and activate each other when photo-stimulated. Evidence that cell bodies of AVPV Kiss1 neurons (that should be GFP labeled) are devoid of mCherry is necessary.

See response to specific comment \#3. Also, we have published that photostimulation of Kiss1^AVPV/PeN^ neurons caused auto-inhibition, not auto-excitation (Qiu et al., 2016, Figure 2I). Therefore, optogenetic activation of AVPV Kiss1 neurons does not activate other AVPV Kiss1 neurons but appears to inhibit each other via GABA release. We have now added higher power confocal images (Figure 6A1-A3) illustrating that mCherry-labeled Kiss1^ARH^ neurons (Figure 6A1) project to the AVPV/PeN area but that the AVPV/PeN does not express mCherry-labeled cells (Figure 6A2), only immunoreactive kisspeptin neurons (Figure 6A3). Also, see Results section and Materials and methods section.

> 5\) Indicate at what time after OVX or E2 replacement the experiments were performed as well as dose of E2 used.

The time of ovariectomy and E2 replacement and dose have been included in the Materials and methods section. Also, E2-treatments during the CPP have been added to Table 2.

> 6\) Subsection "High frequency stimulation of glutamate release from Kiss1^ARH^ neurons excites POMC neurons and inhibits NPY neurons via metabotropic receptors", \"revealed a significantly reduced slow EPSP\" However, Figure 11G does not show this different to be significant.

We have made it clear that we are comparing differences between the control and knockout with E2 replacement (Results section). (The response in E2-treated, OVX females; unpaired t-test, t ~(25)~ = 2.735, p = 0.0113). a-a, p\<0.05) in Figure 11G.

> 7\) Has DHPC been used on NPY neurons and DCG-IV on POMC neurons?

Yes, and we have now included a statement in the Results section that DHPG had no effect on NPY, and DCG-IV had no effect on POMC neurons (see Results section).

> 8\) The authors addressed the role of mGluR2 in NPY neurons, which is expressed only in 10% of them. Therefore, the study of mGluR7, which is more abundant, is missing.

We have now included the electrophysiological responses to mGluR7 agonists in oil and E2-treated OVX females (Results section; Figure 10D-F) and have also illustrated the effects of E2-treatment on mGluR7 mRNA expression in NPY neurons in Figure 10I.

> 9\) E2 dramatically decreases Kiss1 expression (Figure 2) to suggest a decreased Kiss release. As such, it is expected that the Kisspeptin tone onto POMC and NPY neurons would be minimal at high Hz stimulation in OVX-E2 vs. OVX VGluT2 KO mice. Did the authors do these measurements? This should be at least discussed along with potential studies assessing the impact of E2 on responses to Kisspeptin in POMC or NPY neurons.

We did not compare E2-treated, OVX KO versus Oil-treated, OVX vGluT2 KO mice, since we had very few vGluT2 KO animals to work with. But we did compare E2-treated, OVX controls versus E2-treated, OVX vGluT2 KO mice. Please compare Figure 12I,J (KO) with Figure 7B,D (controls), animals in both groups were E2-treated. We have more fully emphasized the significant reduction in the postsynaptic responses in the Results section. In addition, we have discussed the possibility that kisspeptin excitatory action on POMC neurons and inhibitory actions on NPY/AgRP neurons could be one of the reasons why deleting vGluT2 was not effective to alter body weight on standard low fat chow over the time-course of our study (Discussion section).

> 10\) Did the authors test the effect of high Hz stimulation of ARC Kiss1 on AVPV Kiss1 activity in VGluT2 KO mice? This aspect should be at least discussed.

Again, because of the limited number of vGluT2 KO animals, we did not systematically test the effect of high frequency stimulation on the input to the AVPV in vGlut2 KO. The AVPV/PeN Kiss1 neurons do not express Kiss1 or NKB receptors (Navarro et al., 2013). They do express κ receptors (Zhang et al., 2013) and would possibly be inhibited by dynorphin following high frequency stimulation of Kiss1^ARH^ inputs. We do not know if AVPV Kiss1 neurons express metabotropic glutamate receptors. We have added a note in the Discussion section that further studies are needed to determine whether glutamate and/or peptide neurotransmission from Kiss1^ARH^ to Kiss1^AVPV^ neurons are involved in reproductive functions.

\[Editors\' note: further revisions were requested prior to acceptance, as described below.\]

> The manuscript has been largely improved but there is one remaining issue that needs to be addressed before acceptance: could you please add a sentence justifying the use of the OVX and OVX+E2 animal models in the text?

We are pleased that our revised manuscript was favorably evaluated by the editors and reviewers, and we have made the final requested revision by including a sentence in the Materials and methods section justifying the use of OVX and OVX + E2 animal models. In addition, the Padilla et al., manuscript is published, and we have included the complete reference in the Reference list.
